Frederik Barkhof

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8877219/frederik-barkhof-publications-by-year.pdf
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,466 papers	92,271 citations	142 h-index	253 g-index
1,653 ext. papers	107,515 ext. citations	6.6 avg, IF	7.81 L-index

#	Paper	IF	Citations
1466	The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.. *European Radiology*, **2022**, 1	8	0
1465	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline.. *Brain Communications*, **2022**, 4, fcac026	4.5	0
1464	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. *Multiple Sclerosis Journal*, **2022**, 13524585211061861	5	1
1463	The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.. *Multiple Sclerosis and Related Disorders*, **2022**, 57, 103364	4	1
1462	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.. *journal of prevention of Alzheimeris disease, The*, **2022**, 9, 197-210	3.8	7
1461	MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies.. *NeuroImage: Clinical*, **2022**, 34, 102972	5.3	0
1460	Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. *Cerebral Circulation - Cognition and Behavior*, **2022**, 3, 100141	0	0
1459	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. *Cerebral Circulation - Cognition and Behavior*, **2022**, 3, 100128	0	
1458	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.. *Neurology*, **2022**,	6.5	3
1457	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. *Frontiers in Aging Neuroscience*, **2022**, 14, 840651	5.3	0
1456	Response to the 'Letter to the editor'-10.1007/s00234-022-02906-z.. *Neuroradiology*, **2022**, 64, 849	3.2	
1455	Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study.. *Multiple Sclerosis and Related Disorders*, **2022**, 60, 103713	4	0
1454	Quantification of amyloid PET for future clinical use: a state-of-the-art review.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**, 1	8.8	1
1453	Familial British dementia: a clinical and multi-modal imaging case study.. *Journal of Neurology*, **2022**, 1	5.5	
1452	Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.. *Radiology*, **2022**, 211252	20.5	
1451	Impact of cerebral blood flow and amyloid load on SUVR bias.. *EJNMMI Research*, **2022**, 12, 29	3.6	0
1450	Post-mortem correlates of Virchow-Robin spaces detected on MRI.. *Journal of Cerebral Blood Flow and Metabolism*, **2022**, 271678X211067455	7.3	0

1449	Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. *NeuroImage: Clinical*, **2022**, 35, 103048	5.3	3
1448	Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 1421-1431	5	8
1447	Gut Microbiota Composition Is Related to AD Pathology.. *Frontiers in Immunology*, **2021**, 12, 794519	8.4	7
1446	Amyloid-p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's disease.. *Brain Communications*, **2021**, 3, fcab281	4.5	0
1445	Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. *Annals of Clinical and Translational Neurology*, **2021**, 8, 2235	5.3	3
1444	Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. *JAMA Neurology*, **2021**,	17.2	36
1443	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. *Alzheimeris Research and Therapy*, **2021**, 13, 169	9	10
1442	Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence. *Neurology*, **2021**, 97, 989-999	6.5	1
1441	Seeing more with less: virtual gadolinium-enhanced glioma imaging. *The Lancet Digital Health*, **2021**, 3, e754-e755	14.4	0
1440	Degenerative adversarial neuroimage nets for brain scan simulations: Application in ageing and dementia. *Medical Image Analysis*, **2021**, 75, 102257	15.4	0
1439	Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis. *Multiple Sclerosis Journal*, **2021**, 13524585211045545	5	1
1438	A deep learning algorithm for white matter hyperintensity lesion detection and segmentation. *Neuroradiology*, **2021**, 1	3.2	1
1437	Presumed small vessel disease, imaging and cognition markers in the Alzheimer's Disease Neuroimaging Initiative. *Brain Communications*, **2021**, 3, fcab226	4.5	
1436	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services-part 1 of 6. *Alzheimeris Research and Therapy*, **2021**, 13, 168	9	6
1435	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. *Neurology*, **2021**,	6.5	4
1434	Brain structural and functional alterations in MOG antibody disease. *Multiple Sclerosis Journal*, **2021**, 27, 1350-1363	5	5
1433	Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review. *Multiple Sclerosis Journal*, **2021**, 27, 1643-1656	5	11
1432	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. *Journals of Gerontology - Series B Psychological Sciences and Social Sciences*, **2021**, 76, 1499-1511	4.6	4

1431	DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease. *American Journal of Clinical Nutrition*, **2021**, 113, 1627-1635	7	3
1430	Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 709-716	5.5	3
1429	Molecular Imaging Approaches in Dementia. *Radiology*, **2021**, 298, 517-530	20.5	8
1428	Replication study of plasma proteins relating to Alzheimer's pathology. *Alzheimeris and Dementia*, **2021**, 17, 1452-1464	1.2	4
1427	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [F]FDG-PET and pathological assessment. *Neurocase*, **2021**, 27, 181-189	0.8	2
1426	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. *JAMA Neurology*, **2021**, 78, 351-364	17.2	11
1425	Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event. *Brain*, **2021**, 144, 1409-1421	11.2	7
1424	Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications. *Radiology*, **2021**, 299, 3-26	20.5	16
1423	Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 13524585211010097	5	4
1422	Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 20552173211013831	2	1
1421	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. *Alzheimeris and Dementia*, **2021**, 17, 1189-1204	1.2	9
1420	Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy. *Multiple Sclerosis Journal*, **2021**, 13524585211008743	5	4
1419	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. *Alzheimeris Research and Therapy*, **2021**, 13, 82	9	3
1418	Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. *Nature Communications*, **2021**, 12, 2078	17.4	32
1417	Cortical involvement determines impairment 30 years after a clinically isolated syndrome. *Brain*, **2021**, 144, 1384-1395	11.2	6
1416	Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 995-1006	5.5	1
1415	Uncertainty analysis of MR-PET image registration for precision neuro-PET imaging. *NeuroImage*, **2021**, 232, 117821	7.9	1
1414	Spatial concordance of DNA methylation classification in diffuse glioma. *Neuro-Oncology*, **2021**, 23, 2054-2065	11	5

1413	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. *Brain*, **2021**, 144, 1296-1311	11.2	12
1412	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. *Alzheimeris and Dementia*, **2021**, 17, 1628-1640	1.2	4
1411	Glioblastoma Surgery Imaging-Reporting and Data System: Standardized Reporting of Tumor Volume, Location, and Resectability Based on Automated Segmentations. *Cancers*, **2021**, 13,	6.6	2
1410	Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis. *Neurology*, **2021**, 97, e794-e802	6.5	1
1409	Parametric imaging of dual-time window [F]flutemetamol and [F]florbetaben studies. *NeuroImage*, **2021**, 234, 117953	7.9	2
1408	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis. *Neurology*, **2021**, 97, 474-488	6.5	7
1407	The natural history of primary progressive aphasia: beyond aphasia. *Journal of Neurology*, **2021**, 1	5.5	1
1406	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. *Frontiers in Aging Neuroscience*, **2021**, 13, 712545	5.3	3
1405	[F]Flortaucipir PET Across Various Mutations in Presymptomatic and Symptomatic Carriers. *Neurology*, **2021**, 97, e1017-e1030	6.5	3
1404	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. *Multiple Sclerosis Journal*, **2021**, 13524585211024997	5	13
1403	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 28-38	5	8
1402	Are Apathy and Depressive Symptoms Related to Vascular White Matter Hyperintensities in Severe Late Life Depression?. *Journal of Geriatric Psychiatry and Neurology*, **2021**, 34, 21-28	3.8	5
1401	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. *Multiple Sclerosis Journal*, **2021**, 27, 968-972	5	2
1400	Clinical evaluation of automated quantitative MRI reports for assessment of hippocampal sclerosis. *European Radiology*, **2021**, 31, 34-44	8	5
1399	Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	9
1398	Cerebral effects of glucagon-like peptide-1 receptor blockade before and after Roux-en-Y gastric bypass surgery in obese women: A proof-of-concept resting-state functional MRI study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 415-424	6.7	4
1397	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. *Magnetic Resonance Imaging*, **2021**, 76, 108-115	3.3	7
1396	Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 177-188	5.5	3

1395	The sequence of structural, functional and cognitive changes in multiple sclerosis. *NeuroImage: Clinical*, **2021**, 29, 102550	5.3	4
1394	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. *Alzheimeris and Dementia*, **2021**, 17, 205-214	1.2	3
1393	Grey zone amyloid burden affects memory function: the SCIENCe project. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 747-756	8.8	3
1392	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. *NeuroImage: Clinical*, **2021**, 29, 102549	5.3	6
1391	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. *Nature Reviews Neurology*, **2021**, 17, 173-184	15	18
1390	Risk of dementia in 4 carriers is mitigated by a polygenic risk score. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12229	5.2	2
1389	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. *NeuroImage: Clinical*, **2021**, 30, 102660	5.3	3
1388	Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study. *Neuro-Oncology Advances*, **2021**, 3, vdab053	0.9	
1387	Biomarker testing in MCI patients-deciding who to test. *Alzheimeris Research and Therapy*, **2021**, 13, 14	9	0
1386	FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis. *NeuroImage: Clinical*, **2021**, 29, 102542	5.3	2
1385	Amyloid-cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. *Annals of Clinical and Translational Neurology*, **2021**, 8, 348-358	5.3	3
1384	White matter microstructure disruption in early stage amyloid pathology. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12124	5.2	2
1383	Transient Cognitive Impairment and White Matter Hyperintensities in Severely Depressed Older Patients Treated With Electroconvulsive Therapy. *American Journal of Geriatric Psychiatry*, **2021**, 29, 1117-1128	6.5	1
1382	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. *European Radiology*, **2021**, 31, 5312-5323	8	8
1381	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. *NeuroImage: Clinical*, **2021**, 30, 102659	5.3	0
1380	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12216	5.2	1
1379	Visual assessment of [F]flutemetamol PET images can detect early amyloid pathology and grade its extent. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2169-2182	8.8	5
1378	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. *Alzheimeris Research and Therapy*, **2021**, 13, 53	9	7

1377	In vivo tau pathology is associated with synaptic loss and altered synaptic function. *Alzheimeris Research and Therapy*, **2021**, 13, 35	9	15
1376	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. *Journal of Alzheimeris Disease*, **2021**, 79, 1195-1201	4.3	5
1375	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2157-2168	8.8	5
1374	Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**,	5.5	2
1373	On the cutting edge of glioblastoma surgery: where neurosurgeons agree and disagree on surgical decisions. *Journal of Neurosurgery*, **2021**, 1-11	3.2	0
1372	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. *Alzheimeris Research and Therapy*, **2021**, 13, 138	9	4
1371	Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review. *Acta Neuropathologica Communications*, **2021**, 9, 131	7.3	2
1370	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. *Frontiers in Neurology*, **2021**, 12, 693333	4.1	1
1369	Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder. *Multiple Sclerosis Journal*, **2021**, 13524585211032800	5	3
1368	2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. *Lancet Neurology, The*, **2021**, 20, 653-670	24.1	44
1367	Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. *Neurology*, **2021**, 97, e1898-e1905	6.5	12
1366	Non-invasively measured brain activity and radiological progression in diffuse glioma. *Scientific Reports*, **2021**, 11, 18990	4.9	1
1365	Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a systematic review. *Neuroradiology*, **2021**, 63, 1773-1789	3.2	8
1364	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. *Brain Communications*, **2021**, 3, fcab201	4.5	2
1363	MRI Natural History of the Leukodystrophy Vanishing White Matter. *Radiology*, **2021**, 300, 671-680	20.5	3
1362	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. *Neurobiology of Aging*, **2021**, 105, 252-261	5.6	2
1361	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. *NeuroImage: Clinical*, **2021**, 31, 102725	5.3	0
1360	Subtyping relapsing-remitting multiple sclerosis using structural MRI. *Journal of Neurology*, **2021**, 268, 1808-1817	5.5	4

1359	Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. *Neurology*, **2021**, 96, e1561-e1573	6.5	5
1358	The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals. *Alzheimeris and Dementia*, **2021**,	1.2	4
1357	Identifying and evaluating clinical subtypes of Alzheimer's disease in care electronic health records using unsupervised machine learning. *BMC Medical Informatics and Decision Making*, **2021**, 21, 343	3.6	1
1356	Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. *Alzheimeris and Dementia*, **2021**, 17,	1.2	1
1355	A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue.. *Magnetic Resonance Materials in Physics, Biology, and Medicine*, **2021** , 35, 163	2.8	0
1354	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification.. *Alzheimeris and Dementia*, **2021**, 17 Suppl 3, e053030	1.2	
1353	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. *NeuroImage: Clinical*, **2020**, 28, 102504	5.3	5
1352	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. *Alzheimeris and Dementia*, **2020**, 16, e037912	1.2	
1351	Mild cognitive impairment with Lewy bodies: Clinical characteristics and risk factors for progression. *Alzheimeris and Dementia*, **2020**, 16, e039094	1.2	1
1350	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated segmentation in old and young healthy volunteers. *Alzheimeris and Dementia*, **2020**, 16, e040322	1.2	
1349	Amyloid-β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. *Alzheimeris and Dementia*, **2020**, 16, e040991	1.2	
1348	ExploreQC: A toolbox for MRI quality control in the EPAD multicentre study. *Alzheimeris and Dementia*, **2020**, 16, e041952	1.2	
1347	Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCe project. *Alzheimeris and Dementia*, **2020**, 16, e042116	1.2	
1346	Dynamic PET imaging reduces sample sizes to detect longitudinal amyloid accumulation. *Alzheimeris and Dementia*, **2020**, 16, e042623	1.2	1
1345	Differential diagnosis of dementia combining web-based cognitive testing and MRI. *Alzheimeris and Dementia*, **2020**, 16, e042626	1.2	
1344	Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. *Alzheimeris and Dementia*, **2020**, 16, e042628	1.2	
1343	Examining centiloid quantification against visual assessment using [18F]flutemetamol PET. *Alzheimeris and Dementia*, **2020**, 16, e042653	1.2	
1342	Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. *Alzheimeris and Dementia*, **2020**, 16, e042687	1.2	

1341	Biomarker testing in MCI patients: Deciding who to tap. *Alzheimeris and Dementia*, **2020**, 16, e042735	1.2	
1340	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. *Alzheimeris and Dementia*, **2020**, 16, e042739	1.2	
1339	Amyloid-β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. *Alzheimeris and Dementia*, **2020**, 16, e042768	1.2	
1338	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. *Alzheimeris and Dementia*, **2020**, 16, e042892	1.2	
1337	A multi-study analysis of the spatial-temporal progression of amyloid deposition and its utility for longitudinal studies. *Alzheimeris and Dementia*, **2020**, 16, e044707	1.2	
1336	Current status and quantitative results of the AMYPAD prognostic and natural history study. *Alzheimeris and Dementia*, **2020**, 16, e044711	1.2	
1335	Amyloid-dependent association of grey matter network disruptions with phospho-tau in preclinical Alzheimer's disease. *Alzheimeris and Dementia*, **2020**, 16, e044739	1.2	
1334	Converging evidence for a "gray-zone" of amyloid burden and its relevance. *Alzheimeris and Dementia*, **2020**, 16, e044786	1.2	2
1333	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. *Alzheimeris and Dementia*, **2020**, 16, e045196	1.2	
1332	Grey zone amyloid burden heralds future memory decline: The SCIENCe Project. *Alzheimeris and Dementia*, **2020**, 16, e045210	1.2	
1331	Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [18F]flortaucipir, [11C]UCB-J and magnetoencephalography study. *Alzheimeris and Dementia*, **2020**, 16, e045806	1.2	
1330	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. *Alzheimeris and Dementia*, **2020**, 16, e045876	1.2	
1329	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomal-dominant Alzheimer disease depend on imaging modality. *Alzheimeris and Dementia*, **2020**, 16, e045942	1.2	
1328	Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET. *Alzheimeris and Dementia*, **2020**, 16, e045991	1.2	
1327	Damage in the Thalamocortical Tracts is Associated With Subsequent Thalamus Atrophy in Early Multiple Sclerosis. *Frontiers in Neurology*, **2020**, 11, 575611	4.1	0
1326	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. *Journal of Alzheimeris Disease*, **2020**, 74, 213-225	4.3	10
1325	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. *NeuroImage*, **2020**, 218, 116932	7.9	15
1324	ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. *Neurology*, **2020**, 95, e46-e58	6.5	30

1323	ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies. *NeuroImage*, **2020**, 219, 117031	7.9	25
1322	Accurate MR Image Registration to Anatomical Reference Space for Diffuse Glioma. *Frontiers in Neuroscience*, **2020**, 14, 585	5.1	9
1321	Response: Brain miliary enhancement. *Neuroradiology*, **2020**, 62, 547	3.2	
1320	Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance. *Journal of Neurology*, **2020**, 267, 3287-3291	5.5	1
1319	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. *Neurology*, **2020**, 95, e1027-e1040	6.5	11
1318	The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. *Neurobiology of Aging*, **2020**, 95, 104-114	5.6	4
1317	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. *Journal of Neurology*, **2020**, 267, 3541-3554	5.5	8
1316	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. *Nature Reviews Neurology*, **2020**, 16, 171-182	15	68
1315	Author response: Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. *Neurology*, **2020**, 94, 330	6.5	
1314	Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 388-391	5.5	8
1313	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. *Lancet Neurology, The*, **2020**, 19, 214-225	24.1	48
1312	Brain miliary enhancement. *Neuroradiology*, **2020**, 62, 283-300	3.2	7
1311	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. *PLoS ONE*, **2020**, 15, e0226784	3.7	4
1310	Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. *Alzheimeris Research and Therapy*, **2020**, 12, 118	9	54
1309	Using Unsupervised Learning to Identify Clinical Subtypes of Alzheimer's Disease in Electronic Health Records. *Studies in Health Technology and Informatics*, **2020**, 270, 499-503	0.5	4
1308	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. *Efficacy and Mechanism Evaluation*, **2020**, 7, 1-72	1.7	6
1307	An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis: Advocacy, Dissemination, and Implementation Strategies. *International Journal of MS Care*, **2020**, 22, 226-232	2.3	5
1306	Demyelinating Diseases of the CNS (Brain and Spine). *IDKD Springer Series*, **2020**, 165-176	1.1	5

1305	Learning to Segment When Experts Disagree. *Lecture Notes in Computer Science*, **2020**, 179-190	0.9	3
1304	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2020**, 94, 71-80	5.6	7
1303	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. *Brain*, **2020**, 143, 3776-3792	11.2	16
1302	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. *Brain Communications*, **2020**, 2, fcaa177	4.5	3
1301	Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. *Stroke*, **2020**, 51, 170-178	6.7	53
1300	Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods. *European Radiology*, **2020**, 30, 1062-1074	8	16
1299	The P2X receptor tracer [C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 379-389	8.8	30
1298	A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. *Annals of Neurology*, **2020**, 87, 63-74	9.4	37
1297	Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI. *Alzheimeris Research and Therapy*, **2020**, 12, 10	9	6
1296	Generalised boundary shift integral for longitudinal assessment of spinal cord atrophy. *NeuroImage* , **2020**, 209, 116489	7.9	10
1295	CSF cutoffs for MCI due to AD depend on APOE4 carrier status. *Neurobiology of Aging*, **2020**, 89, 55-62	5.6	7
1294	Why Is Amyloid-PET Requested After Performing CSF Biomarkers?. *Journal of Alzheimeris Disease*, **2020**, 73, 559-569	4.3	5
1293	White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. *Human Brain Mapping*, **2020**, 41, 1309-1322	5.9	13
1292	Comorbid amyloid-pathology affects clinical and imaging features in VCD. *Alzheimeris and Dementia*, **2020**, 16, 354-364	1.2	3
1291	Hippocampal profiling: Localized magnetic resonance imaging volumetry and T2 relaxometry for hippocampal sclerosis. *Epilepsia*, **2020**, 61, 297-309	6.4	9
1290	Robust Deep Learning-based Segmentation of Glioblastoma on Routine Clinical MRI Scans Using Sparsified Training. *Radiology: Artificial Intelligence*, **2020**, 2, e190103	8.7	5
1289	Spinal cord atrophy in a primary progressive multiple sclerosis trial: Improved sample size using GBSI. *NeuroImage: Clinical*, **2020**, 28, 102418	5.3	6
1288	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. *Lancet Neurology, The*, **2020**, 19, 951-962	24.1	95

1287	MS-SMART study: systematic sampling bias concerns - Authors' reply. *Lancet Neurology, The*, **2020**, 19, 479-480	24.1	
1286	Multitracer model for staging cortical amyloid deposition using PET imaging. *Neurology*, **2020**, 95, e1538-e1553	6.5	20
1285	Relationship between β-amyloid and structural network topology in decedents without dementia. *Neurology*, **2020**, 95, e532-e544	6.5	3
1284	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. *Neurology*, **2020**, 95, e1672-e1685	6.5	9
1283	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. *Alzheimeris Research and Therapy*, **2020**, 12, 148	9	6
1282	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. *Translational Psychiatry*, **2020**, 10, 403	8.6	10
1281	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. *American Journal of Neuroradiology*, **2020**, 41, 2209-2218	4.4	5
1280	Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. *Neurology*, **2020**, 95, e745-e754	6.5	17
1279	Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12060	5.2	2
1278	Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12077	5.2	1
1277	Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis. *Brain*, **2020**, 143, 2988-2997	11.2	7
1276	Cerebral blood flow and cognitive functioning in patients with disorders along the heart-brain axis: Cerebral blood flow and the heart-brain axis. *Alzheimeris and Dementia: Translational Research and Clinical Interventions*, **2020**, 6, e12034	6	5
1275	In vivo imaging of chronic active lesions in multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 1352458520958589	5	12
1274	Pathologic correlates of the magnetization transfer ratio in multiple sclerosis. *Neurology*, **2020**, 95, e2965-e2976	6.5	13
1273	Sex differences in memory clinic patients with possible vascular cognitive impairment. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12090	5.2	2
1272	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. *Journal of Alzheimeris Disease*, **2020**, 77, 1353-1368	4.3	4
1271	Sex differences in CSF biomarkers vary by Alzheimer disease stage and ε4 genotype. *Neurology*, **2020**, 95, e2378-e2388	6.5	20
1270	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. *Alzheimeris and Dementia*, **2020**, 16, 1457-1468	1.2	16

1269	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12063	5.2	5
1268	Immune signatures of prodromal multiple sclerosis in monozygotic twins. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 21546-21556	11.5	12
1267	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. *Brain*, **2020**, 143, 2831-2843	11.2	29
1266	Quantifying eloquent locations for glioblastoma surgery using resection probability maps. *Journal of Neurosurgery*, **2020**, 134, 1091-1101	3.2	7
1265	A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 774-785	5	8
1264	Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 476-488	5	26
1263	Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. *Neuro-Oncology*, **2020**, 22, 412-422	1	24
1262	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2020**, 75, 1609-1617	6.4	5
1261	Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?. *Multiple Sclerosis Journal*, **2020**, 26, 1381-1391	5	9
1260	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. *Brain Imaging and Behavior*, **2020**, 14, 2012-2023	4.1	17
1259	Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. *Multiple Sclerosis Journal*, **2020**, 26, 1372-1380	5	16
1258	Single-subject structural cortical networks in clinically isolated syndrome. *Multiple Sclerosis Journal*, **2020**, 26, 1392-1401	5	3
1257	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. *Alzheimeris and Dementia*, **2020**, 16, 750-758	1.2	11
1256	Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm. *Annals of Neurology*, **2020**, 88, 93-105	9.4	26
1255	Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. *Neuroradiology*, **2020**, 62, 1257-1263	3.2	2
1254	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. *Movement Disorders*, **2020**, 35, 859-867	7	13
1253	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784		
1252	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784		

1251	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784		
1250	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784		
1249	Randomized trial of daily high-dose vitamin D in patients with RRMS receiving subcutaneous interferon β1a. *Neurology*, **2019**, 93, e1906-e1916	6.5	37
1248	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. *Brain*, **2019**, 142, 2787-2799	11.2	64
1247	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. *Neurology*, **2019**, 93, e1778-e1786	6.5	22
1246	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. *Alzheimeris and Dementia*, **2019**, 15, 1478-1488	1.2	22
1245	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. *Lancet Neurology, The*, **2019**, 18, 1034-1044	24.1	45
1244	Voxelwise statistical methods to localize practice variation in brain tumor surgery. *PLoS ONE*, **2019**, 14, e0222939	3.7	4
1243	Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis. *Neurology*, **2019**, 93, e1348-e1359	6.5	25
1242	Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 69-73	5.2	6
1241	Novel imaging phantom for accurate and robust measurement of brain atrophy rates using clinical MRI. *NeuroImage: Clinical*, **2019**, 21, 101667	5.3	2
1240	Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort. *Alzheimeris Research and Therapy*, **2019**, 11, 12	9	24
1239	The presence of cerebral white matter lesions and lower skin microvascular perfusion predicts lower cognitive performance in type 1 diabetes patients with retinopathy but not in healthy controls-A longitudinal study. *Microcirculation*, **2019**, 26, e12530	2.9	5
1238	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. *Lancet Neurology, The*, **2019**, 18, 185-197	24.1	74
1237	Lifespan normative data on rates of brain volume changes. *Neurobiology of Aging*, **2019**, 81, 30-37	5.6	24
1236	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. *Brain*, **2019**, 142, 1858-1875	11.2	150
1235	High-dimensional detection of imaging response to treatment in multiple sclerosis. *Npj Digital Medicine*, **2019**, 2, 49	15.7	8
1234	Non-linear registration improves statistical power to detect hippocampal atrophy in aging and dementia. *NeuroImage: Clinical*, **2019**, 23, 101902	5.3	5

1233	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 997-1004	5.5	13
1232	Neuromyelitis Optica Spectrum Disorders (NMOSD) **2019**, 1-17		
1231	Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab. *Multiple Sclerosis and Related Disorders*, **2019**, 33, 82-87	4	9
1230	Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease. *Human Brain Mapping*, **2019**, 40, 3900-3909	5.9	10
1229	Automated fiber tract reconstruction for surgery planning: Extensive validation in language-related white matter tracts. *NeuroImage: Clinical*, **2019**, 23, 101883	5.3	11
1228	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. *Alzheimeris and Dementia*, **2019**, 15, 817-827	1.2	26
1227	IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease. *Lancet Neurology, The*, **2019**, 18, 519-520	24.1	
1226	Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 11020-11027	11.1	13
1225	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 383-391	5.2	37
1224	The Meta VCI Map consortium for meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping: Design and multicenter pilot study. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 310-326	5.2	12
1223	Inflammatory biomarkers in Alzheimer's disease plasma. *Alzheimeris and Dementia*, **2019**, 15, 776-787	1.2	74
1222	Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. *Alzheimeris Research and Therapy*, **2019**, 11, 33	9	22
1221	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. *Journal of Alzheimeris Disease*, **2019**, 68, 1273-1286	4.3	4
1220	Standardized Assessment of Automatic Segmentation of White Matter Hyperintensities and Results of the WMH Segmentation Challenge. *IEEE Transactions on Medical Imaging*, **2019**, 38, 2556-2568	11.7	87
1219	Cortical cerebral blood flow in ageing: effects of haematocrit, sex, ethnicity and diabetes. *European Radiology*, **2019**, 29, 5549-5558	8	14
1218	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 22, 101786	5.3	13
1217	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. *Neurology*, **2019**, 92, e1558-e1566	6.5	14
1216	Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. *Neuroradiology*, **2019**, 61, 633-642	3.2	25

1215	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. *Alzheimeris and Dementia*, **2019**, 15, 644-654	1.2	57
1214	Normal Aging Brain Collection Amsterdam (NABCA): A comprehensive collection of postmortem high-field imaging, neuropathological and morphometric datasets of non-neurological controls. *NeuroImage: Clinical*, **2019**, 22, 101698	5.3	9
1213	Leukodystrophies and Inherited Metabolic Conditions **2019**, 1-36		
1212	Comparing Glioblastoma Surgery Decisions Between Teams Using Brain Maps of Tumor Locations, Biopsies, and Resections. *JCO Clinical Cancer Informatics*, **2019**, 3, 1-12	5.2	20
1211	Automatically computed rating scales from MRI for patients with cognitive disorders. *European Radiology*, **2019**, 29, 4937-4947	8	11
1210	Inter-rater agreement in glioma segmentations on longitudinal MRI. *NeuroImage: Clinical*, **2019**, 22, 101727	5.3	41
1209	Detecting frontotemporal dementia syndromes using MRI biomarkers. *NeuroImage: Clinical*, **2019**, 22, 101711	5.3	21
1208	Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder. *European Radiology*, **2019**, 29, 4670-4677	8	17
1207	Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 44-46	5.5	16
1206	Validation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanner effects. *NeuroImage: Clinical*, **2019**, 24, 101962	5.3	11
1205	Association between tumor location and neurocognitive functioning using tumor localization maps. *Journal of Neuro-Oncology*, **2019**, 144, 573-582	4.8	14
1204	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. *Neurobiology of Aging*, **2019**, 84, 225-234	5.6	16
1203	The quantitative neuroradiology initiative framework: application to dementia. *British Journal of Radiology*, **2019**, 92, 20190365	3.4	12
1202	Leukodystrophies and Inherited Metabolic Conditions **2019**, 1641-1675		
1201	Multiple Sclerosis and Variants **2019**, 727-767		
1200	Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. *Annals of Neurology*, **2019**, 86, 704-713	9.4	22
1199	Medial temporal lobe atrophy and posterior atrophy scales normative values. *NeuroImage: Clinical*, **2019**, 24, 101936	5.3	8
1198	Neuromyelitis Optica Spectrum Disorders (NMOSD) **2019**, 769-785		0

1197	Direct comparison of [C] choline and [F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. *EJNMMI Research*, **2019**, 9, 57	3.6	4
1196	Neuroimaging in Normal Brain Aging **2019**, 1277-1293		
1195	Neuroimaging in Dementia **2019**, 1295-1325		
1194	Neurodegenerative Disorders: Classification and Imaging Strategy **2019**, 1251-1275		
1193	Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. *Brain*, **2019**, 142, 2276-2287	11.2	65
1192	Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 24, 101954	5.3	19
1191	Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 463-471	5.2	15
1190	Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship. *Neurology*, **2019**, 93, e334-e346	6.5	47
1189	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. *Journal of Neurology*, **2019**, 266, 2535-2545	5.5	6
1188	Reproducing Fingerprints: A Step toward Clinical Adoption. *Radiology*, **2019**, 292, 438-439	20.5	
1187	and cortical superficial siderosis in CAA: Meta-analysis and potential mechanisms. *Neurology*, **2019**, 93, e358-e371	6.5	25
1186	Associations between quantitative [F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum. *Alzheimeris Research and Therapy*, **2019**, 11, 60	9	18
1185	Applying the ATN scheme in a memory clinic population: The ABIDE project. *Neurology*, **2019**, 93, e1635-e1646	6.5	32
1184	Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. *Neurology*, **2019**, 93, e1852-e1866	6.5	22
1183	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. *Alzheimeris and Dementia*, **2019**, 15, 1458-1467	1.2	11
1182	Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process. *NeuroImage: Clinical*, **2019**, 24, 102051	5.3	2
1181	SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis. *NeuroImage: Clinical*, **2019**, 24, 102011	5.3	23
1180	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. *Alzheimeris and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 492-500	6	4

1179	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion symptom mapping study. *Journal of Psychiatry and Neuroscience*, **2019**, 44, E1-E10	4.5	7
1178	Differences in topological progression profile among neurodegenerative diseases from imaging data. *ELife*, **2019**, 8,	8.9	8
1177	TADPOLE Challenge: Accurate Alzheimer's disease prediction through crowdsourced forecasting of future data. *Lecture Notes in Computer Science*, **2019**, 11843, 1-10	0.9	14
1176	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. *Journal of Alzheimeris Disease*, **2019**, 68, 311-322	4.3	8
1175	Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. *Journal of Clinical Investigation*, **2019**, 129, 4758-4768	15.9	43
1174	Can MRI be used as a proxy for ? A case study. *Brain Communications*, **2019**, 1, fcz030	4.5	8
1173	IC-P-159: AMYLOID-BETA ACCUMULATION AFFECTS IN VIVO STAGING OF TAU DEPOSITION IN COGNITIVELY IMPAIRED INDIVIDUALS **2019**, 15, P127-P128		
1172	IC-P-025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE **2019**, 15, P32-P33		
1171	Comparing lesion segmentation methods in multiple sclerosis: Input from one manually delineated subject is sufficient for accurate lesion segmentation. *NeuroImage: Clinical*, **2019**, 24, 102074	5.3	13
1170	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. *Scientific Reports*, **2019**, 9, 16742	4.9	20
1169	IC-02-01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE **2019**, 15, P1-P1		
1168	IC-P-076: FDG-PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELY-DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE **2019**, 15, P68-P70		
1167	IC-P-015: VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM **2019**, 15, P24-P25		
1166	IC-P-097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING **2019**, 15, P84-P85		
1165	PET and CSF amyloid- status are differently predicted by patient features: information from discordant cases. *Alzheimeris Research and Therapy*, **2019**, 11, 100	9	17
1164	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. *Brain Imaging and Behavior*, **2019**, 13, 1361-1374	4.1	14
1163	Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. *Neurology*, **2019**, 92, 180-192	6.5	50
1162	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. *Multiple Sclerosis Journal*, **2019**, 25, 1915-1925	5	57

1161	Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease-specific regions. *Neurobiology of Aging*, **2019**, 75, 109-116	5.6	10
1160	Preoperative Resectability Estimates of Nonenhancing Glioma by Neurosurgeons and a Resection Probability Map. *Neurosurgery*, **2019**, 85, E304-E313	3.2	10
1159	Predicting clinical progression in multiple sclerosis after 6 and 12 years. *European Journal of Neurology*, **2019**, 26, 893-902	6	24
1158	Exploring resting state connectivity in patients with psychotic depression. *PLoS ONE*, **2019**, 14, e0209908	3.7	5
1157	AMYPAD Diagnostic and Patient Management Study: Rationale and design. *Alzheimeris and Dementia*, **2019**, 15, 388-399	1.2	19
1156	Assessing Amyloid Pathology in Cognitively Normal Subjects Using F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. *Journal of Nuclear Medicine*, **2019**, 60, 541-547	8.9	33
1155	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies. *Alzheimeris and Dementia*, **2019**, 15, 185-193	1.2	19
1154	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. *Multiple Sclerosis Journal*, **2019**, 25, 565-573	5	4
1153	Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. *Multiple Sclerosis Journal*, **2019**, 25, 352-360	5	11
1152	Gray matter networks and cognitive impairment in multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 382-391	5	21
1151	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. *Nature Reviews Neurology*, **2018**, 14, 199-213	15	95
1150	Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. *Neurology*, **2018**, 90, e1183-e1190	6.5	50
1149	White matter hyperintensities and vascular risk factors in monozygotic twins. *Neurobiology of Aging* , **2018**, 66, 40-48	5.6	9
1148	Cortical and subcortical gray matter structural alterations in normoglycemic obese and type 2 diabetes patients: relationship with adiposity, glucose, and insulin. *Metabolic Brain Disease*, **2018**, 33, 1211-1222	3.9	15
1147	Accelerated executive functions decline and gray matter structural changes in middle-aged type 1 diabetes mellitus patients with proliferative retinopathy. *Journal of Diabetes*, **2018**, 10, 835-846	3.8	6
1146	Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. *Journal of Alzheimeris Disease*, **2018**, 62, 1827-1839	4.3	22
1145	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. *Human Brain Mapping*, **2018**, 39, 3143-3151	5.9	26
1144	The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Commentary. *Multiple Sclerosis Journal*, **2018**, 24, 125-126	5	2

1143	Linking late cognitive outcome with glioma surgery location using resection cavity maps. *Human Brain Mapping*, **2018**, 39, 2064-2074	5.9	28
1142	Microbleeds are associated with depressive symptoms in Alzheimer's disease. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 112-120	5.2	5
1141	'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. *Developmental Medicine and Child Neurology*, **2018**, 60, 417-423	3.3	45
1140	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. *Lancet Neurology, The*, **2018**, 17, 133-142	24.1	66
1139	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurology, The*, **2018** , 17, 162-173	24.1	2419
1138	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. *Nature Reviews Neurology*, **2018**, 14, 75-93	15	84
1137	Deep gray matter volume loss drives disability worsening in multiple sclerosis. *Annals of Neurology*, **2018**, 83, 210-222	9.4	185
1136	Peri-hippocampal developmental venous anomalies and memory loss: more than a normal variant?. *Neuroradiology*, **2018**, 60, 579-582	3.2	
1135	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. *Alzheimeris Research and Therapy*, **2018**, 10, 23	9	13
1134	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. *NeuroImage: Clinical*, **2018**, 19, 466-475	5.3	33
1133	Progressive brain rich-club network disruption from clinically isolated syndrome towards multiple sclerosis. *NeuroImage: Clinical*, **2018**, 19, 232-239	5.3	17
1132	Evaluation of prospective motion correction of high-resolution 3D-T2-FLAIR acquisitions in epilepsy patients. *Journal of Neuroradiology*, **2018**, 45, 368-373	3.1	5
1131	Cerebral Microbleeds: Imaging and Clinical Significance. *Radiology*, **2018**, 287, 11-28	20.5	115
1130	Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. *JAMA Neurology*, **2018**, 75, 827-833	17.2	18
1129	Cerebral rituximab uptake in multiple sclerosis: A Zr-immunoPET pilot study. *Multiple Sclerosis Journal*, **2018**, 24, 543-545	5	15
1128	Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 491-500	5	13
1127	Brain reward responses to food stimuli among female monozygotic twins discordant for BMI. *Brain Imaging and Behavior*, **2018**, 12, 718-727	4.1	11
1126	Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. *European Radiology*, **2018**, 28, 96-103	8	16

1125	Multimodal characterization of gray matter alterations in neuromyelitis optica. *Multiple Sclerosis Journal*, **2018**, 24, 1308-1316	5	10
1124	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. *Neurobiology of Aging*, **2018**, 61, 238-244	5.6	18
1123	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. *Neurobiology of Aging*, **2018**, 61, 75-81	5.6	29
1122	The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study. *European Radiology*, **2018**, 28, 1215-1226	8	6
1121	Differential brainstem atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders. *Journal of Magnetic Resonance Imaging*, **2018**, 47, 1601-1609	5.6	9
1120	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. *Neurobiology of Aging*, **2018**, 61, 198-206	5.6	25
1119	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. *Alzheimeris Research and Therapy*, **2018**, 10, 72	9	25
1118	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. *Journal of Alzheimeris Disease*, **2018**, 65, 71-77	4.3	2
1117	Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. *Brain*, **2018**, 141, 2605-2618	11.2	74
1116	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. *Frontiers in Aging Neuroscience*, **2018**, 10, 111	5.3	21
1115	Disrupted Module Efficiency of Structural and Functional Brain Connectomes in Clinically Isolated Syndrome and Multiple Sclerosis. *Frontiers in Human Neuroscience*, **2018**, 12, 138	3.3	18
1114	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. *Alzheimeris Research and Therapy*, **2018**, 10, 64	9	31
1113	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. *Frontiers in Aging Neuroscience*, **2018**, 10, 67	5.3	18
1112	Evaluating combinations of diagnostic tests to discriminate different dementia types. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 509-518	5.2	12
1111	Functional brain network centrality is related to APOE genotype in cognitively normal elderly. *Brain and Behavior*, **2018**, 8, e01080	3.4	9
1110	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. *Journal of Psychiatric Research*, **2018**, 104, 183-191	5.2	15
1109	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. *Alzheimeris Research and Therapy*, **2018**, 10, 76	9	56
1108	Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. *Neurology*, **2018**, 91, e1130-e1134	6.5	20

1107	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. *JAMA Neurology*, **2018**, 75, 1062-1070	17.2	70
1106	Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study. *Neurology*, **2018**, 91, e249-e257	6.5	18
1105	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. *JMIR Research Protocols*, **2018**, 7, e80	2	3
1104	Bullseye's representation of cerebral white matter hyperintensities. *Journal of Neuroradiology*, **2018**, 45, 114-122	3.1	19
1103	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. *Neurology*, **2018**, 90, e149-e156	6.5	68
1102	Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 481-490	5	10
1101	Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 535-541	5.5	19
1100	P1-401: INVESTIGATING ARTERIAL SPIN LABELING AS A LARGE VESSEL CORRELATE OF SVD, AD, AND PD **2018**, 14, P456-P456		3
1099	P3-403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE **2018**, 14, P1257-P1257		
1098	O3-13-01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE **2018**, 14, P1054-P1055		
1097	P1-476: CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS **2018**, 14, P506-P507		
1096	O1-14-04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION-SYMPTOM MAPPING STUDY **2018**, 14, P259-P259		
1095	P3-216: IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOGY OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIF-AD 90+ STUDY **2018**, 14, P1153-P1153		
1094	IC-P-222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM **2018**, 14, P180-P181		
1093	IC-P-066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS **2018**, 14, P59-P60		
1092	IC-P-182: EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL AMYLOID DEPOSITION IN THE BRAIN **2018**, 14, P152-P152		1
1091	P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2018**, 14, P1161-P1161		
1090	P1-016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAM-VCI STUDY **2018**, 14, P270-P271		

1089 IC-P-119: POSTERIOR ATROPHY SCALE: NORMATIVE VALUES FOR ITALIAN POPULATION **2018**, 14, P101-P102

1088 IC-06-05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE **2018**, 14, P13-P13

1087 P1-418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS **2018**, 14, P465-P465

1086 P2-505: REGIONAL DISTRIBUTION OF WHITE MATTER HYPERINTENSITY CORRELATES WITH COGNITION IN THE ALFA COHORT **2018**, 14, P925-P925 1

1085 IC-P-092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY **2018**, 14, P76-P79 1

1084 P4-106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD **2018**, 14, P1479-P1479 1

1083 P1-297: METABOLIC BLOOD-BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE **2018**, 14, P401-P403

1082 P1-478: LOWER STRUCTURAL DEGREE AND HIGHER LOCAL EFFICIENCY RELATED TO DIFFUSE AMYLOID-BETA LOAD IN CORTEX OF NON-NEUROLOGICAL AGED DONORS **2018**, 14, P508-P508

1081 P2-349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA **2018**, 14, P820-P821

1080 P2-363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS **2018**, 14, P830-P831

1079 F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P204-P204

1078 P3-436: MECHANISTIC PROFILES OF NEURODEGENERATION: A STUDY IN ALZHEIMER'S DISEASE, HEALTHY AGEING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS **2018**, 14, P1280-P1281

1077 P2-360: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM **2018**, 14, P827-P829

1076 P3-264: UNBIASED METHOD TO DETERMINE CUT-POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION **2018**, 14, P1176-P1177

1075 O2-03-03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY **2018**, 14, P615-P617

1074 P01.062 Probability maps of glioblastoma indicate variation in surgical decisions between twelve surgical teams. *Neuro-Oncology*, **2018**, 20, iii243-iii244 1 78

1073 O2-14-04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATE-ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY **2018**, 14, P657-P658

1072 IC-P-093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS **2018**, 14, P79-P80

1071 IC-P-033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE **2018**, 14, P37-P38

1070 P3-342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI-STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES **2018**, 14, P1214-P1215

1069 IC-P-032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI-STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES **2018**, 14, P36-P37

1068 IC-P-192: DISEASE-STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P158-P160 2

1067 P3-277: IMPAIRMENT IN COMPLEX ACTIVITIES OF DAILY LIVING IS RELATED TO NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECIFIC REGIONS **2018**, 14, P1183-P1184

1066 THUR 174 The magnify-ms study: mavenclad tablets in active rms. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, A23.1-A23 5.5

1065 P3-348: POSTERIOR ATROPHY SCALE: NORMATIVE VALUES FOR ITALIAN POPULATION **2018**, 14, P1217-P1218

1064 IC-P-122: THE NORMAL AGING BRAIN COLLECTION AMSTERDAM (NABCA): A COMPREHENSIVE COLLECTION OF POSTMORTEM IMAGING, NEUROPATHOLOGICAL AND MORPHOMETRIC DATASETS **2018**, 14, P103-P104

1063 IC-P-110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE **2018**, 14, P94-P95

1062 F5-05-04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P1633-P1633

1061 P1-467: DISEASE-STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P500-P501

1060 O2-09-05: EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES **2018**, 14, P643-P643

1059 P3-422: PROTOCOL HARMONISATION AND IN-VIVO COMPARISON OF ARTERIAL SPIN LABELLING PERFUSION MRI FOR MULTICENTER CLINICAL TRIALS **2018**, 14, P1269-P1271

1058 O2-15-04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS **2018**, 14, P661-P662

1057 O5-01-03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NON-NEGATIVE MATRIX FACTORIZATION **2018**, 14, P1638-P1639

1056 IC-P-005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [18F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS **2018**, 14, P16-P17

1055 O2-13-03: REGIONAL DISTRIBUTION OF WHITE MATTER HYPERINTENSITIES RELATED TO ALZHEIMER'S DISEASE RISK FACTORS IN THE ALFA COHORT **2018**, 14, P653-P654

1054 P2-445: EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL AMYLOID DEPOSITION IN THE BRAIN **2018**, 14, P887-P888 1

1053	A novel partial volume correction method for accurate quantification of [F] flortaucipir in the hippocampus. *EJNMMI Research*, **2018**, 8, 79	3.6	15
1052	Multiple Sclerosis and Variants **2018**, 1-41		1
1051	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [F]DPA714 PET. *Journal of Neuroinflammation*, **2018**, 15, 314	10.1	45
1050	F1-02-02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION **2018**, 14, P201-P202		
1049	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. *BMC Geriatrics*, **2018**, 18, 289	4.1	15
1048	IC-P-053: LOWER STRUCTURAL DEGREE AND HIGHER LOCAL EFFICIENCY RELATED TO DIFFUSE AMYLOID-BETA LOAD IN CORTEX OF NON-NEUROLOGICAL AGED DONORS **2018**, 14, P51-P51		
1047	Computer-assisted prediction of clinical progression in the earliest stages of AD. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 726-736	5.2	8
1046	P3-355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [18F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS **2018**, 14, P1221-P1222		
1045	P2-477: THE NORMAL AGING BRAIN COLLECTION AMSTERDAM (NABCA): A COMPREHENSIVE COLLECTION OF POSTMORTEM IMAGING, NEUROPATHOLOGICAL AND MORPHOMETRIC DATASETS **2018**, 14, P907-P908		
1044	F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO A APOE 4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P201-P201		
1043	Neuroimaging in Dementia **2018**, 1-31		
1042	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. *Alzheimeris Research and Therapy*, **2018**, 10, 100	9	30
1041	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. *Frontiers in Aging Neuroscience*, **2018**, 10, 279	5.3	27
1040	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. *Alzheimeris Research and Therapy*, **2018**, 10, 112	9	27
1039	Cardiovascular Risk Factors and White Matter Hyperintensities: Difference in Susceptibility in South Asians Compared With Europeans. *Journal of the American Heart Association*, **2018**, 7, e010533	6	14
1038	P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY **2018**, 14, P895-P896		
1037	F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY **2018**, 14, P202-P204		
1036	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. *Brain*, **2018**, 141, 3443-3456	11.2	49

1035	Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions **2018**, 59, 5025-5031		11
1034	IC-P-187: CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS **2018**, 14, P156-P156		
1033	Clinical phenotype, atrophy, and small vessel disease in carriers with Alzheimer disease. *Neurology*, **2018**, 91, e1851-e1859	6.5	30
1032	The hippocampus in multiple sclerosis. *Lancet Neurology, The*, **2018**, 17, 918-926	24.1	57
1031	Neurodegenerative Disorders: Classification and Imaging Strategy **2018**, 1-26		
1030	The EMIF-AD PreclinAD study: study design and baseline cohort overview. *Alzheimeris Research and Therapy*, **2018**, 10, 75	9	24
1029	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. *BMJ Open*, **2018**, 8, e021944	3	26
1028	Neuroimaging in Normal Brain Aging **2018**, 1-17		
1027	Progression of regional grey matter atrophy in multiple sclerosis. *Brain*, **2018**, 141, 1665-1677	11.2	146
1026	Earliest radiological progression in glioblastoma by multidisciplinary consensus review. *Journal of Neuro-Oncology*, **2018**, 139, 591-598	4.8	2
1025	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. *NeuroImage: Clinical*, **2018**, 19, 625-632	5.3	18
1024	The European DTI Study on Dementia - A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. *NeuroImage*, **2017**, 144, 305-308	7.9	15
1023	Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities. *Journal of Neuroimaging*, **2017**, 27, 318-325	2.8	6
1022	Interaction of Vascular Damage and Alzheimer Dementia: Focal Damage and Disconnection. *Radiology*, **2017**, 282, 311-313	20.5	8
1021	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. *Journal of Neuro-Oncology*, **2017**, 132, 255-266	4.8	34
1020	Subcutaneous interferon a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 285-294	5.5	23
1019	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 6, 143-151	5.2	43
1018	Diagnostic algorithm for relapsing demyelinating syndromes of the CNS in children. *Lancet, The*, **2017**, 389, S41	40	2

1017	rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 386-394	5.5	33
1016	APOE ε4 status is associated with white matter hyperintensities volume accumulation rate independent of AD diagnosis. *Neurobiology of Aging*, **2017**, 53, 67-75	5.6	24
1015	4H Leukodystrophy: A Brain Magnetic Resonance Imaging Scoring System. *Neuropediatrics*, **2017**, 48, 152-160	1.6	12
1014	Increased default-mode network centrality in cognitively impaired multiple sclerosis patients. *Neurology*, **2017**, 88, 952-960	6.5	60
1013	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. *Multiple Sclerosis Journal*, **2017**, 23, 1909-1917	5	17
1012	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. *Alzheimeris and Dementia*, **2017**, 13, 1226-1236	1.2	45
1011	Altered eigenvector centrality is related to local resting-state network functional connectivity in patients with longstanding type 1 diabetes mellitus. *Human Brain Mapping*, **2017**, 38, 3623-3636	5.9	22
1010	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 908-916	5.5	45
1009	Increased connectivity of hub networks and cognitive impairment in multiple sclerosis. *Neurology*, **2017**, 88, 2107-2114	6.5	41
1008	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE-e4 Homozygosity. *Journal of Alzheimeris Disease*, **2017**, 56, 63-74	4.3	23
1007	Impact of Gradient Number and Voxel Size on Diffusion Tensor Imaging Tractography for Resective Brain Surgery. *World Neurosurgery*, **2017**, 105, 923-934.e2	2.1	6
1006	Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. *NeuroImage: Clinical*, **2017**, 15, 613-624	5.3	23
1005	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. *Human Brain Mapping*, **2017**, 38, 4703-4715	5.9	39
1004	Disrupted white matter structural networks in healthy older adult APOE ε4 carriers - An international multicenter DTI study. *Neuroscience*, **2017**, 357, 119-133	3.9	23
1003	Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. *Neurology*, **2017**, 89, 269-278	6.5	117
1002	Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. *European Radiology*, **2017**, 27, 4237-4246	8	23
1001	Connectomic profile and clinical phenotype in newly diagnosed glioma patients. *NeuroImage: Clinical*, **2017**, 14, 87-96	5.3	40
1000	Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. *Alzheimeris and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 157-165	6	12

999	Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients. *Journal of Alzheimeris Disease*, **2017**, 57, 557-573	4.3	30
998	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. *Neurobiology of Aging*, **2017**, 52, 167-182.e1	5.6	51
997	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. *Lancet Neurology, The*, **2017**, 16, 965-975	24.1	118
996	Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues. *Diabetes Care*, **2017**, 40, 1522-1529	14.6	37
995	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. *JAMA Neurology*, **2017**, 74, 1481-1491	17.2	58
994	Imaging outcome measures for progressive multiple sclerosis trials. *Multiple Sclerosis Journal*, **2017**, 23, 1614-1626	5	42
993	[IC-P-130]: MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY **2017**, 13, P98-P99		
992	[P1□92]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA **2017**, 13, P417-P418		
991	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. *Alzheimeris Research and Therapy*, **2017**, 9, 73	9	20
990	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. *Alzheimeris Research and Therapy*, **2017**, 9, 95	9	243
989	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. *NeuroImage*, **2017**, 163, 106-114	7.9	18
988	Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. *American Journal of Neuroradiology*, **2017**, 38, 1884-1891	4.4	35
987	Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy. *NeuroImage: Clinical*, **2017**, 15, 843-853	5.3	20
986	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 9, 76-83	5.2	29
985	[P2□45]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER's DISEASE PATIENTS WITH CURCUMIN **2017**, 13, P705-P706		
984	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. *Lancet Neurology, The*, **2017**, 16, 661-676	24.1	308
983	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. *Alzheimeris and Dementia*, **2017**, 13, 531-540	1.2	64
982	Early- and Late-Onset Depression in Late Life: A Prospective Study on Clinical and Structural Brain Characteristics and Response to Electroconvulsive Therapy. *American Journal of Geriatric Psychiatry*, **2017**, 25, 178-189	6.5	41

981	Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. *Multiple Sclerosis Journal*, **2017**, 23, 656-664	5	29
980	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. *European Radiology*, **2017**, 27, 1169-1175	8	65
979	A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2017**, 174, 220-226	3.5	5
978	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. *Neurobiology of Aging*, **2017**, 50, 77-86	5.6	3
977	[P2□99]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P783-P783		
976	[P2□18]: METHODOLOGICAL AND LOGISTIC STRATEGIES FOR A LARGE MULTI-CENTER □AMYLOID PET EUROPEAN PROJECT: AMYLOID IMAGING TO PREVENT ALZHEIMER's DISEASE (AMYPAD) **2017**, 13, P794-P794		
975	[P3□62]: ACROSS-SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI-SITE 3T STUDY **2017**, 13, P954-P955		
974	[P3□75]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT **2017**, 13, P1102-P1103		
973	[P3□86]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI **2017**, 13, P1108-P1108		1
972	[P3□89]: WHEN MEASURING HIPPOCAMPAL ATROPHY, DO THE SEGMENTATION NOISE DISTRIBUTIONS OF METHODS, AS DETERMINED BY THE BACK-TO-BACK REPRODUCIBILITY, HAVE GAUSSIAN DISTRIBUTIONS? **2017**, 13, P1109-P1111		
971	[P3□22]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA **2017**, 13, P1127-P1128		
970	[P4□26]: BEST COMBINATORIAL LOW-COST MARKERS TO PREDICT MCI CONVERSION: AN EMIF-AD FEDERATION STUDY **2017**, 13, P1356-P1357		
969	[IC-P-036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P32-P32		
968	[IC-P-053]: EARLY ALTERATIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS **2017**, 13, P43-P44		
967	[IC-P-055]: EFFECT OF APOE-□ ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE **2017**, 13, P45-P46		
966	[IC-P-065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P53-P54		
965	[IC-P-085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT **2017**, 13, P69-P69		
964	[IC-P-095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE **2017**, 13, P74-P75		

963 [IC-P-106]: PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE **2017**, 13, P81-P82

962 [IC-P-110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P87-P87

961 [IC-P-132]: WHEN MEASURING HIPPOCAMPAL ATROPHY, DO THE SEGMENTATION NOISE DISTRIBUTIONS OF METHODS, AS DETERMINED BY THE BACK TO BACK REPRODUCIBILITY, HAVE GAUSSIAN DISTRIBUTIONS? **2017**, 13, P99-P101

960 [IC-P-167]: ACROSS-SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI-SITE 3T STUDY **2017**, 13, P126-P127

959 [P1289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2017**, 13, P361-P362

958 [P1395]: AMYPAD: A EUROPEAN PUBLIC-PRIVATE PARTNERSHIP TO INVESTIGATE THE VALUE OF AMYLOID BRAIN SCANS AS A DIAGNOSTIC AND THERAPEUTIC MARKER FOR ALZHEIMER's DISEASE **2017**, 13, P420-P420 1

957 [P1400]: USING SUBTRACTION MRI TO IMPROVE THE DETECTION OF AMYLOID-RELATED IMAGING ABNORMALITIES WITH EDEMA OR EFFUSION (ARIA-E) IN PATIENTS AFFECTED BY ALZHEIMER's DISEASE RECEIVING IMMUNOTHERAPY: AN INTER-OBSERVER STUDY **2017**, 13, P425-P427

956 [P1404]: EARLY ALTERATIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS **2017**, 13, P429-P429

955 [P1411]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P433-P434

954 [P1440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P451-P451

953 [P2212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY **2017**, 13, P691-P692 1

952 [P2335]: EFFECT OF APOE ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE **2017**, 13, P748-P750

951 [F1030304]: BIOMARKER-BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P177

950 [O101102]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE **2017**, 13, P182

949 [O201101]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE) **2017**, 13, P547-P548

948 [O210106]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM **2017**, 13, P579

947 [O211103]: PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE **2017**, 13, P581-P582

946 [P4524]: WHITE MATTER HYPERINTENSITIES ARE ASSOCIATED WITH HIPPOCAMPAL ATROPHY RATES AFTER ADJUSTING FOR OTHER VASCULAR MARKERS IN PREDEMENTIA DISEASE STAGES **2017**, 13, P1547-P1548

945	[P4□26]: HARMONIZATION OF NEUROIMAGING BIORMARKERS FOR NEURODEGENERATIVE DISEASES: A SURVEY FOR BEST PRACTICE GUIDELINES **2017**, 13, P1549-P1550		
944	[DT-01□2]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT **2017**, 13, P1474-P1475		
943	HOUT-14. TIME TO PROGRESSION AND VOLUME AT PROGRESSION DEPEND ON DEFINITION OF PROGRESSION IN GLIOBLASTOMA. *Neuro-Oncology*, **2017**, 19, vi108-vi109	1	78
942	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. *Frontiers in Aging Neuroscience*, **2017**, 9, 117	5.3	44
941	Regional analysis of volumes and reproducibilities of automatic and manual hippocampal segmentations. *PLoS ONE*, **2017**, 12, e0166785	3.7	12
940	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. *Journal of Alzheimeris Disease*, **2017**, 55, 521-537	4.3	31
939	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-□*Journal of Alzheimeris Disease*, **2017**, 55, 333-342	4.3	12
938	The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. *Brain Connectivity*, **2016**, 6, 1-8	2.7	14
937	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 468-75	5.5	109
936	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 425-32	5.5	63
935	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. *NeuroImage*, **2016**, 124, 442-454	7.9	58
934	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 235-43	5.5	58
933	Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes. *Diabetes Care*, **2016**, 39, 214-21	14.6	45
932	Quantitative MRI in hypomyelinating disorders: Correlation with motor handicap. *Neurology*, **2016**, 87, 752-8	6.5	8
931	Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. *Dementia and Geriatric Cognitive Disorders*, **2016**, 41, 210-9	2.6	21
930	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. *Lecture Notes in Computer Science*, **2016**, 87-96	0.9	12
929	P2-250: Reduced White Matter Integrity of the Rostral Limbic System Pathways in Healthy Elderly APOE E4 Allele Carriers **2016**, 12, P721-P721		
928	Disrupted topological organization of structural and functional brain connectomes in clinically isolated syndrome and multiple sclerosis. *Scientific Reports*, **2016**, 6, 29383	4.9	47

927	Arterial Spin Labeling Perfusion of the Brain: Emerging Clinical Applications. *Radiology*, **2016**, 281, 337-356	6.5	225
926	P2-342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function **2016**, 12, P774-P774		
925	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic **2016**, 12, P393-P393		1
924	ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, e1.30-e1	5.5	
923	P07.08 Higher functional hub load at diagnosis is associated with shorter survival in glioma patients. *Neuro-Oncology*, **2016**, 18, iv35-iv35	1	78
922	Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study): A Diagnostic Study Protocol. *Neurosurgery*, **2016**, 79, 535-40	3.2	15
921	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. *Human Brain Mapping*, **2016**, 37, 2114-32	5.9	27
920	Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study. *Multiple Sclerosis Journal*, **2016**, 22, 901-9	5	29
919	Brain atrophy measurements should be used to guide therapy monitoring in MS - NO. *Multiple Sclerosis Journal*, **2016**, 22, 1524-1526	5	14
918	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. *Human Brain Mapping*, **2016**, 37, 978-88	5.9	32
917	Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. *Human Brain Mapping*, **2016**, 37, 1194-208	5.9	19
916	Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study. *Human Brain Mapping*, **2016**, 37, 1627-44	5.9	65
915	Cortical phase changes measured using 7-T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. *NMR in Biomedicine*, **2016**, 29, 1289-94	4.4	9
914	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. *Lancet Neurology, The*, **2016**, 15, 292-303	24.1	486
913	Multi-scale MRI spectrum detects differences in myelin integrity between MS lesion types. *Multiple Sclerosis Journal*, **2016**, 22, 1569-1577	5	13
912	Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. *Journal of Endocrinology*, **2016**, 229, 1-12	4.7	35
911	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. *Dementia and Geriatric Cognitive Disorders*, **2016**, 41, 16-26	2.6	8
910	Multicenter Validation of Mean Upper Cervical Cord Area Measurements from Head 3D T1-Weighted MR Imaging in Patients with Multiple Sclerosis. *American Journal of Neuroradiology*, **2016**, 37, 749-54	4.4	22

909	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. *Radiology*, **2016**, 279, 838-48	20.5	52
908	Cerebral perfusion in the predementia stages of Alzheimer's disease. *European Radiology*, **2016**, 26, 506-14	4	69
907	Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. *Multiple Sclerosis Journal*, **2016**, 22, 1174-83	5	19
906	Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. *Brain*, **2016**, 139, 115-26	11.2	161
905	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. *Brain*, **2016**, 139, 1211-25	11.2	135
904	White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. *American Journal of Neuroradiology*, **2016**, 37, 1030-7	4.4	7
903	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. *Neurobiology of Aging*, **2016**, 38, 21-31	5.6	32
902	Alterations in white matter volume and integrity in obesity and type 2 diabetes. *Metabolic Brain Disease*, **2016**, 31, 621-9	3.9	43
901	Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. *Brain*, **2016**, 139, 1472-81	11.2	100
900	Whole brain functional connectivity in clinically isolated syndrome without conventional brain MRI lesions. *European Radiology*, **2016**, 26, 2982-91	8	11
899	High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 1279-88	5	27
898	Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 1306-14	5	18
897	Gray matter network disruptions and amyloid beta in cognitively normal adults. *Neurobiology of Aging*, **2016**, 37, 154-160	5.6	41
896	Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 608-19	5	31
895	MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 879-84	5.5	40
894	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. *Journal of Alzheimeris Disease*, **2016**, 50, 261-70	4.3	12
893	Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 106-12	5.5	23
892	Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method. *PLoS ONE*, **2016**, 11, e0143942	3.7	33

891	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. *Lecture Notes in Computer Science*, **2016**, 104-112	0.9	1
890	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. *Brain*, **2016**, 139, 2528-39	11.2	45
889	Differential Dementia Diagnosis on Incomplete Data with Latent Trees. *Lecture Notes in Computer Science*, **2016**, 44-52	0.9	1
888	Causes, effects and connectivity changes in MS-related cognitive decline. *Dementia E Neuropsychologia*, **2016**, 10, 2-11	2.1	7
887	Novel MRI and PET markers of neuroinflammation in multiple sclerosis. *Current Opinion in Neurology*, **2016**, 29, 229-36	7.1	20
886	Subgenual Cingulate Cortex Functional Connectivity in Relation to Depressive Symptoms and Cognitive Functioning in Type 1 Diabetes Mellitus Patients. *Psychosomatic Medicine*, **2016**, 78, 740-9	3.7	12
885	Postmortem validation of MRI cortical volume measurements in MS. *Human Brain Mapping*, **2016**, 37, 2223-33	5.9	23
884	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. *Radiology*, **2016**, 281, 865-875	20.5	44
883	MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1138-45	5.5	44
882	Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. *Journal of Alzheimeris Disease*, **2016**, 53, 1287-97	4.3	37
881	Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1296-1302	5.5	31
880	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2016**, 5, 43-52	5.2	30
879	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients **2016**, 12, P9-P10		
878	P2-221: Cerebral Blood Flow Measured with Phase-Contrast MRI in AD, MCI and Controls **2016**, 12, P706-P706		
877	O3-08-01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status **2016**, 12, P303-P303		
876	P1-178: Impact of Co-Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders **2016**, 12, P472-P472		
875	IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs **2016**, 12, P7-P8		
874	P1-284: Grey Matter Connectivity is Associated With Clinical Progression in Non-Demented, Amyloid Positive Patients **2016**, 12, P528-P529		

873	P1-327: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease **2016**, 12, P552-P553		
872	IC-P-103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer Disease **2016**, 12, P78-P79		
871	IC-P-106: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease **2016**, 12, P80-P81		
870	IC-P-108: Cerebral Blood Flow Measured With Phase-Contrast MRI in AD, MCI and Controls **2016**, 12, P82-P82		
869	IC-P-133: The Measurement of Hippocampal Atrophy Rates With MRI for A 3-Year Study Appears to be at Least 3 Times More Sensitive Than A 1-Year Study Based on Back-To-Back Reproducibility **2016**, 12, P99-P100		
868	IC-P-147: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology **2016**, 12, P109-P110		
867	P3-144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts **2016**, 12, P873-P874		
866	IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function **2016**, 12, P113-P114		0
865	P3-269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs **2016**, 12, P935-P936		
864	P4-191: A Novel Neuroimaging Approach to Capture Cognitive Reserve **2016**, 12, P1095-P1096		
863	P4-220: The Measurement of Hippocampal Atrophy Rates With MRI for A 3-Year Study Appears to Be at Least 3 Times More Sensitive Than A 1-Year Study Based on Back-To-Back Reproducibility **2016**, 12, P1112-P1113		
862	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer Disease **2016**, 12, P169-P170		
861	O4-02-04: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology **2016**, 12, P335-P336		
860	O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases **2016**, 12, P355-P355		
859	P1-174: Cost-Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach **2016**, 12, P469-P470		
858	Neuroimaging in Dementia **2016**, 79-85		4
857	Impact of APOE-e4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. *Neurobiology of Aging*, **2016**, 38, 14-20	5.6	26
856	Differential diagnosis of neurodegenerative diseases using structural MRI data. *NeuroImage: Clinical*, **2016**, 11, 435-449	5.3	81

855	Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease. *Psychiatry Research - Neuroimaging*, **2016**, 252, 26-35	2.9	18
854	Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. *Alzheimeris and Dementia: Translational Research and Clinical Interventions*, **2016**, 2, 233-240	6	4
853	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. *Neurology*, **2016**, 87, 978-87	8.5	78
852	What drives MRI-measured cortical atrophy in multiple sclerosis?. *Multiple Sclerosis Journal*, **2015**, 21, 1280-90	5	66
851	Arterial spin labeling may contribute to the prediction of cognitive deterioration in healthy elderly individuals. *Radiology*, **2015**, 274, 490-9	20.5	97
850	The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. *Alzheimeris and Dementia*, **2015**, 11, 111-25	1.2	137
849	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 2340-7	5.6	40
848	Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis. *American Journal of Neuroradiology*, **2015**, 36, 1116-23	4.4	15
847	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. *Brain*, **2015**, 138, 2732-49	11.2	275
846	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. *Nature Reviews Neurology*, **2015**, 11, 471-82	15	272
845	Transient gadolinium leakage in natalizumab-treated multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 475-6	5.5	
844	Multimodal Quantitative MR Imaging of the Thalamus in Multiple Sclerosis and Neuromyelitis Optica. *Radiology*, **2015**, 277, 784-92	20.5	30
843	Long-term motor and behavioral outcome after perinatal hypoxic-ischemic encephalopathy. *European Journal of Paediatric Neurology*, **2015**, 19, 354-9	3.8	28
842	Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity. *Multiple Sclerosis Journal*, **2015**, 21, 1705-12	5	47
841	Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis. *Neurology*, **2015**, 85, 248-55	6.5	31
840	Language comprehension in nonspeaking children with severe cerebral palsy: Neuroanatomical substrate?. *European Journal of Paediatric Neurology*, **2015**, 19, 510-20	3.8	10
839	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. *European Radiology*, **2015**, 25, 3050-9	8	65
838	Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study. *Human Brain Mapping*, **2015**, 36, 2809-25	5.9	55

837	Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study. *Journal of Neurology*, **2015**, 262, 1074-80	5.5	18
836	Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 1225-33	5.5	84
835	Differential patterns of spinal cord and brain atrophy in NMO and MS. *Neurology*, **2015**, 84, 1465-72	6.5	60
834	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1939-49	27.4	379
833	Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. *Neurology*, **2015**, 84, 508-15	6.5	96
832	Laminar cortical damage in multiple sclerosis. *Brain*, **2015**, 138, 828-9	11.2	4
831	MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. *Lancet Neurology, The*, **2015**, 14, 443-54	24.1	81
830	Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. *JAMA Neurology*, **2015**, 72, 539-45	17.2	39
829	Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. *Diabetologia*, **2015**, 58, 2688-98	10.3	58
828	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. *Stroke* , **2015**, 46, 2661-4	6.7	51
827	Structural MRI substrates of cognitive impairment in neuromyelitis optica. *Neurology*, **2015**, 85, 1491-9	6.5	47
826	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. *Neurology*, **2015**, 85, 1694-701	6.5	39
825	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. *JAMA Neurology*, **2015**, 72, 1433-41	17.2	50
824	Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images. *NeuroImage: Clinical*, **2015**, 8, 367-75	5.3	149
823	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. *Nature Reviews Neurology*, **2015**, 11, 597-606	15	321
822	Highly accurate volumetry of the spinal cord **2015**,		2
821	Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. *Nature Reviews Neurology*, **2015**, 11, 676-86	15	93
820	Altered cerebrovascular reactivity velocity in mild cognitive impairment and Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 33-41	5.6	57

819	7T T2-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 20-6	5.6	31
818	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. *Neuro-Oncology*, **2015**, 17, 160-6	1	87
817	Disturbed phase relations in white matter hyperintensity based vascular dementia: an EEG directed connectivity study. *Clinical Neurophysiology*, **2015**, 126, 497-504	4.3	17
816	Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 419-24	5.5	79
815	MRI pattern in asymptomatic natalizumab-associated PML. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 793-8	5.5	63
814	Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 410-8	5.5	88
813	Minimal supportive treatment in natalizumab-related PML in a MS patient. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 354-5	5.5	5
812	Perivascular spaces in MS patients at 7 Tesla MRI: a marker of neurodegeneration?. *Multiple Sclerosis Journal*, **2015**, 21, 155-62	5	37
811	IC-P-106: Reproducibility of hippocampal atrophy rate at 1.5T and 3T for freesurfer and MAPS-HBSI using the ADNI1 data set **2015**, 11, P72-P73		
810	P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly **2015**, 11, P689-P689		
809	P3-146: Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment: A multicenter DTI and volumetry study **2015**, 11, P682-P682		
808	IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia **2015**, 11, P85-P85		
807	P4-088: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease **2015**, 11, P806-P806		
806	Volumetric MRI data correlate to disease severity in metachromatic leukodystrophy. *Annals of Clinical and Translational Neurology*, **2015**, 2, 932-40	5.3	14
805	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. *Journal of Alzheimeris Disease*, **2015**, 48, 711-20	4.3	47
804	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study. *Journal of Alzheimeris Disease*, **2015**, 48, 197-204	4.3	41
803	More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer's disease. *Journal of Alzheimeris Disease*, **2015**, 44, 635-47	4.3	36
802	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease **2015**, 11, P414-P414		

801	SUSTAINED LOW RATE BRAIN VOLUME LOSS IN LONG TERM FINGOLIMOD TREATMENT. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, e4.19-e4	5.5	
800	IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease **2015**, 11, P57-P57		
799	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease **2015**, 11, P806-P807		1
798	IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly **2015**, 11, P11-P11		
797	IC-P-092: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning **2015**, 11, P64-P64		
796	IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease **2015**, 11, P46-P47		
795	Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. *Diabetes, Obesity and Metabolism*, **2015**, 17, 878-86	6.7	65
794	Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation. *Obesity*, **2015**, 23, 2075-82	8	40
793	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly. *Human Brain Mapping*, **2015**, 36, 3516-27	5.9	31
792	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. *Frontiers in Human Neuroscience*, **2015**, 9, 474	3.3	45
791	Early-Stage White Matter Lesions Detected by Multispectral MRI Segmentation Predict Progressive Cognitive Decline. *Frontiers in Neuroscience*, **2015**, 9, 455	5.1	16
790	EFFECT OF FINGOLIMOD VS. IFN-BETA1A ON NO EVIDENCE OF DISEASE ACTIVITY. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, e4.18-e4	5.5	
789	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. *Alzheimeris and Dementia*, **2015**, 11, 1191-201	1.2	59
788	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. *Human Brain Mapping*, **2015**, 36, 4421-37	5.9	142
787	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. *NeuroImage: Clinical*, **2015**, 9, 418-29	5.3	26
786	F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease **2015**, 11, P168-P168		
785	Contribution of white matter hyperintensities, medial temporal lobe atrophy and cortical atrophy on outcome, seven to twelve years after ECT in severely depressed geriatric patients. *Journal of Affective Disorders*, **2015**, 185, 144-8	6.6	9
784	IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent? **2015**, 11, P62-P62		

783	IC-P-093: Distinct patterns of atrophy in postmortem confirmed dementias **2015**, 11, P64-P65		
782	IC-P-105: Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment: A multicenter DTI and volumetry study **2015**, 11, P72-P72		
781	IC-P-108: Impact of ApoE-4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults **2015**, 11, P73-P73		
780	P3-170: Reproducibility of hippocampal atrophy rate at 1.5T and 3T for freesurfer and MAPS-HBSI using the ADNI1 data set **2015**, 11, P694-P695		
779	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent? **2015**, 11, P814-P814		
778	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset **2015**, 11, P140-P142		
777	O2-09-01: Impact of ApoE-e4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults **2015**, 11, P194-P194		
776	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool **2015**, 11, P254-P255		
775	O4-08-05: Distinct patterns of atrophy in postmortem-confirmed dementias **2015**, 11, P288-P289		
774	O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning **2015**, 11, P289-P289		
773	O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression **2015**, 11, P317-P317		
772	Functional brain networks: linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study. *Human Brain Mapping*, **2015**, 36, 603-18	5.9	67
771	Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 1605.e13-20	5.6	22
770	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge. *NeuroImage*, **2015**, 111, 562-79	7.9	193
769	Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. *Neurology*, **2015**, 84, 776-83	6.5	123
768	Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusion-Tensor and Magnetic Resonance Imaging Data. *Journal of Neuroimaging*, **2015**, 25, 738-47	2.8	62
767	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. *Neurology*, **2015**, 84, 784-93	6.5	93
766	Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis. *Human Brain Mapping*, **2015**, 36, 1796-807	5.9	47

765	Imaging phenotypes in multiple sclerosis. *Neuroimaging Clinics of North America*, **2015**, 25, 83-96	3	6
764	Head-to-head comparison of two popular cortical thickness extraction algorithms: a cross-sectional and longitudinal study. *PLoS ONE*, **2015**, 10, e0117692	3.7	38
763	Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. *European Radiology*, **2014**, 24, 841-9	8	66
762	Validation of the automated method VIENA: an accurate, precise, and robust measure of ventricular enlargement. *Human Brain Mapping*, **2014**, 35, 1101-10	5.9	18
761	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 1190-8	8.8	7
760	An algorithmic approach to structural imaging in dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 692-8	5.5	71
759	MRI mimics of multiple sclerosis. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2014**, 122, 291-316	3	40
758	Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: an MEG source-space study. *NeuroImage*, **2014**, 88, 308-18	7.9	100
757	The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 1704-13	5	34
756	Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). *Multiple Sclerosis and Related Disorders*, **2014**, 3, 355-63	4	14
755	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. *Multiple Sclerosis Journal*, **2014**, 20, 1692-8	5	41
754	White matter hyperintensities and cognitive impairment during electroconvulsive therapy in severely depressed elderly patients. *American Journal of Geriatric Psychiatry*, **2014**, 22, 157-66	6.5	23
753	Head motion parameters in fMRI differ between patients with mild cognitive impairment and Alzheimer disease versus elderly control subjects. *Brain Topography*, **2014**, 27, 801-7	4.3	12
752	Vitamin D as an early predictor of multiple sclerosis activity and progression. *JAMA Neurology*, **2014**, 71, 306-14	17.2	312
751	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. *Annals of Clinical and Translational Neurology*, **2014**, 1, 605-17	5.3	39
750	GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. *Diabetes*, **2014**, 63, 4186-96	0.9	198
749	Differentiation of edema and glioma infiltration: proposal of a DTI-based probability map. *Journal of Neuro-Oncology*, **2014**, 120, 187-98	4.8	25
748	Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes. *Diabetologia*, **2014**, 57, 2208-14	10.3	31

747	Resting-state functional MR imaging: a new window to the brain. *Radiology*, **2014**, 272, 29-49	20.5	223
746	Ventral striatum, but not cortical volume loss, is related to cognitive dysfunction in type 1 diabetic patients with and without microangiopathy. *Diabetes Care*, **2014**, 37, 2483-90	14.6	26
745	The SIENA/FSL whole brain atrophy algorithm is no more reproducible at 3T than 1.5 T for Alzheimer's disease. *Psychiatry Research - Neuroimaging*, **2014**, 224, 14-21	2.9	12
744	Sex-specific extent and severity of white matter damage in multiple sclerosis: implications for cognitive decline. *Human Brain Mapping*, **2014**, 35, 2348-58	5.9	49
743	Changes in MEG resting-state networks are related to cognitive decline in type 1 diabetes mellitus patients. *NeuroImage: Clinical*, **2014**, 5, 69-76	5.3	18
742	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. *Multiple Sclerosis Journal*, **2014**, 20, 1471-7	5	22
741	Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers. *Human Brain Mapping*, **2014**, 35, 2383-93	5.9	84
740	Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?. *Journal of Neurology*, **2014**, 261, 1139-43	5.5	25
739	Morphological features of MS lesions on FLAIR* at 7□T and their relation to patient characteristics. *Journal of Neurology*, **2014**, 261, 1356-64	5.5	30
738	Structural degree predicts functional network connectivity: a multimodal resting-state fMRI and MEG study. *NeuroImage*, **2014**, 97, 296-307	7.9	87
737	Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. *Lancet Neurology, The*, **2014**, 13, 807-22	24.1	153
736	Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds, which is part of generalized microangiopathy. *Diabetes Care*, **2014**, 37, 1165-8	14.6	50
735	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. *European Radiology*, **2014**, 24, 2326-33	8	46
734	Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. *NeuroImage: Clinical*, **2014**, 4, 366-73	5.3	32
733	Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*, **2014**, 83, 278-86	6.5	1632
732	Daclizumab in multiple sclerosis: a high-yield extension study. *Lancet Neurology, The*, **2014**, 13, 443-4	24.1	1
731	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. *Alzheimeris and Dementia*, **2014**, 10, S299-305	1.2	24
730	The structure of the geriatric depressed brain and response to electroconvulsive therapy. *Psychiatry Research - Neuroimaging*, **2014**, 222, 1-9	2.9	20

729	Optimizing patient care and research: the Amsterdam Dementia Cohort. *Journal of Alzheimeris Disease*, **2014**, 41, 313-27	4.3	243
728	The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. *Alzheimeris Research and Therapy*, **2014**, 6, 47	9	17
727	P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION **2014**, 10, P402-P402		1
726	O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY **2014**, 10, P291-P292		
725	P2-192: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA **2014**, 10, P541-P542		1
724	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA **2014**, 10, P194-P195		
723	P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE **2014**, 10, P385-P386		
722	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE **2014**, 10, P48-P49		
721	IC-P-067: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA **2014**, 10, P37-P37		
720	P1-235: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS **2014**, 10, P390-P391		
719	P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE **2014**, 10, P455-P456		
718	Multicenter R2* mapping in the healthy brain. *Magnetic Resonance in Medicine*, **2014**, 71, 1103-7	4.4	13
717	O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS **2014**, 10, P178-P179		
716	O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA **2014**, 10, P300-P300		
715	IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS **2014**, 10, P32-P33		
714	IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY **2014**, 10, P43-P44		
713	IC-P-224: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS **2014**, 10, P120-P121		
712	O4-07-05: ADDED VALUE OF MRI BIOMARKERS TO NEUROPSYCHOLOGICAL TEST PERFORMANCE FOR PREDICTION OF AD IN SUBJECTS WITH MCI **2014**, 10, P265-P265		1

711	IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS **2014**, 10, P42-P43		0
710	P1-255: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSD STUDY **2014**, 10, P400-P401		1
709	IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE **2014**, 10, P31-P32		
708	IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE **2014**, 10, P61-P61		1
707	P1-233: MULTIMODAL BRAIN NETWORK ALTERATIONS IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT PATIENTS **2014**, 10, P389-P390		
706	P2-196: RESTING STATE CEREBRAL PERFUSION AND METABOLISM IN SUBJECTIVE MEMORY COMPLAINTS: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA□WO SIDES OF THE SAME COIN? **2014**, 10, P543-P543		1
705	O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD **2014**, 10, P132-P133		
704	IC-P-179: REDUCED CALLOSAL WHITE MATTER INTEGRITY SURPASSES CEREBROSPINAL FLUID AND ATROPHY MARKERS AS PREDICTOR OF DECLINE IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT: A COMBINED VOLUMETRY AND DTI STUDY **2014**, 10, P100-P100		
703	P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME **2014**, 10, P363-P363		
702	P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT **2014**, 10, P465-P466		
701	P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS **2014**, 10, P540-P541		
700	Widespread disruption of functional brain organization in early-onset Alzheimer's disease. *PLoS ONE*, **2014**, 9, e102995	3.7	40
699	Functional connectivity and cognitive decline over 3 years in Parkinson disease. *Neurology*, **2014**, 83, 2046-53	6.5	105
698	Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 1183-9	5.5	59
697	Quantification of cerebral blood flow in healthy volunteers and type 1 diabetic patients: comparison of MRI arterial spin labeling and [(15)O]H2O positron emission tomography (PET). *Journal of Magnetic Resonance Imaging*, **2014**, 40, 1300-9	5.6	26
696	Single-subject gray matter graph properties and their relationship with cognitive impairment in early- and late-onset Alzheimer's disease. *Brain Connectivity*, **2014**, 4, 337-46	2.7	46
695	The Dutch Parelsnoer Institute--Neurodegenerative diseases; methods, design and baseline results. *BMC Neurology*, **2014**, 14, 254	3.1	42
694	Efficacy of subcutaneous interferon □1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 647-53	5.5	16

693	Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 202-13	5	24
692	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. *Multiple Sclerosis Journal*, **2014**, 20, 72-80	5	81
691	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. *Neurology*, **2014**, 82, 1768-75	6.5	42
690	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. *Multiple Sclerosis Journal*, **2014**, 20, 234-42	5	17
689	Prevalence of cortical superficial siderosis in a memory clinic population. *Neurology*, **2014**, 82, 698-704	6.5	60
688	Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability. *Multiple Sclerosis Journal*, **2014**, 20, 1860-5	5	56
687	P16.12BRAIN LOCATIONS INVOLVED IN BASELINE COGNITIVE FUNCTIONING OF PATIENTS WITH GLIOMA BEFORE THERAPY. *Neuro-Oncology*, **2014**, 16, ii80-ii81	1	78
686	IC-P-072: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSD STUDY **2014**, 10, P40-P40		1
685	Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. *Neurology: Neuroimmunology and NeuroInflammation*, **2014**, 1, e18	9.1	99
684	What explains gray matter atrophy in long-standing multiple sclerosis?. *Radiology*, **2014**, 272, 832-42	20.5	57
683	Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. *Radiology*, **2014**, 270, 205-11	20.5	62
682	Amyloid and its association with default network integrity in Alzheimer's disease. *Human Brain Mapping*, **2014**, 35, 779-91	5.9	28
681	Longitudinal absolute metabolite quantification of white and gray matter regions in healthy controls using proton MR spectroscopic imaging. *NMR in Biomedicine*, **2014**, 27, 304-11	4.4	18
680	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35, 2665-2670	5.6	23
679	Disruption of structural and functional networks in long-standing multiple sclerosis. *Human Brain Mapping*, **2014**, 35, 5946-61	5.9	60
678	Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?. *Multiple Sclerosis Journal*, **2014**, 20, 1131-4	5	14
677	Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study. *Human Brain Mapping*, **2014**, 35, 5799-814	5.9	54
676	Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. *Current Opinion in Neurology*, **2014**, 27, 260-70	7.1	47

675	Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 1058-65	5	49
674	Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. *JAMA Neurology*, **2014**, 71, 855-62	17.2	113
673	Spinal cord MRI should always be performed in clinically isolated syndrome patients: Yes. *Multiple Sclerosis Journal*, **2014**, 20, 1688-9	5	5
672	Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 412-7	5	52
671	Differential impact of subclinical carotid artery disease on cerebral structure and functioning in type 1 diabetes patients with versus those without proliferative retinopathy. *Cardiovascular Diabetology*, **2014**, 13, 58	8.7	3
670	Hippocampal volume change measurement: quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. *NeuroImage*, **2014**, 92, 169-81	7.9	94
669	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. *Multiple Sclerosis and Related Disorders*, **2014**, 3, 147-55	4	43
668	Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study. *American Journal of Geriatric Psychiatry*, **2014**, 22, 735-40	6.5	22
667	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. *European Radiology*, **2014**, 24, 397-404	8	25
666	Patient subgroup analyses of the treatment effect of subcutaneous interferon β1a on development of multiple sclerosis in the randomized controlled REFLEX study. *Journal of Neurology* , **2014**, 261, 490-9	5.5	12
665	Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial. *PLoS ONE*, **2014**, 9, e94483	3.7	10
664	Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data. *Human Brain Mapping*, **2013**, 34, 52-61	5.9	81
663	Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. *Journal of Neurology*, **2013**, 260, 2458-71	5.5	83
662	Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. *Journal of Neurology*, **2013**, 260, 2016-22	5.5	47
661	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. *Journal of Neurology*, **2013**, 260, 2023-32	5.5	72
660	Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 281-8	5	18
659	Brain atrophy and lesion load predict long term disability in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1082-91	5.5	209
658	Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study. *NeuroImage: Clinical*, **2013**, 2, 727-34	5.3	25

657	Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurology, The*, **2013**, 12, 822-38	24.1	2662
656	Multiple sclerosis: CCSVI deconstructed and discarded. *Nature Reviews Neurology*, **2013**, 9, 661-2	15	4
655	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. *Neurobiology of Aging*, **2013**, 34, 73-82	5.6	38
654	Microglial activation in Alzheimer's disease: an (R)-[□□C]PK11195 positron emission tomography study. *Neurobiology of Aging*, **2013**, 34, 128-36	5.6	126
653	Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. *Neurobiology of Aging*, **2013**, 34, 238-47	5.6	24
652	Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. *European Radiology*, **2013**, 23, 528-40	8	50
651	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. *Neurobiology of Aging*, **2013**, 34, 2003-13	5.6	69
650	Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. *Lancet Neurology, The*, **2013**, 12, 233-43	24.1	146
649	Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2014-22	5.6	120
648	Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs). *NeuroImage: Clinical*, **2013**, 3, 462-9	5.3	137
647	Imaging markers for Alzheimer disease: which vs how. *Neurology*, **2013**, 81, 487-500	6.5	173
646	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2488-94	5.6	59
645	Diffusion changes predict cognitive and functional outcome: the LADIS study. *Annals of Neurology*, **2013**, 73, 576-83	9.4	53
644	An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. *American Journal of Neuroradiology*, **2013**, 34, 1550-5	4.4	24
643	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. *Neurology*, **2013**, 80, 234-41	6.5	42
642	Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. *Neurology*, **2013**, 80, 69-75	6.5	118
641	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. *Neurobiology of Aging*, **2013**, 34, 2023-36	5.6	279
640	Efficient use of MRI for dose finding in multiple sclerosis. *Lancet Neurology, The*, **2013**, 12, 730-1	24.1	

639	Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease. *NeuroImage*, **2013**, 66, 28-35	7.9	63
638	The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. *Multiple Sclerosis Journal*, **2013**, 19, 1826-40	5	78
637	Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. *Radiology*, **2013**, 267, 221-30	20.5	170
636	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. *Neurology*, **2013**, 80, 359-65	6.5	80
635	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. *Neurology*, **2013**, 80, 1048-56	6.5	131
634	Language comprehension in young people with severe cerebral palsy in relation to language tracts: a diffusion tensor imaging study. *Neuropediatrics*, **2013**, 44, 286-90	1.6	5
633	Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1176-7	5.5	36
632	Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. *Journal of Clinical Oncology*, **2013**, 31, 3378-88	2.2	93
631	PS12 - 6. Selective cognitive decline is related to focal brain volume loss in type 1 diabetes patients with microangiopathy: a 4 year follow-up. *Nederlands Tijdschrift Voor Diabetologie*, **2013**, 11, 179-180	0	
630	Cortical imaging in multiple sclerosis: recent findings and 'grand challenges'. *Current Opinion in Neurology*, **2013**, 26, 345-52	7.1	23
629	Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. *Neurology*, **2013**, 80, 1025-32	6.5	121
628	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. *Radiology*, **2013**, 269, 542-552	20.5	109
627	Multicontrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR. *American Journal of Neuroradiology*, **2013**, 34, 791-6	4.4	52
626	Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 593-600	5	84
625	PML in a patient treated with dimethyl fumarate from a compounding pharmacy. *New England Journal of Medicine*, **2013**, 368, 1658-9	59.2	155
624	Associations between magnetic resonance imaging measures and neuropsychological impairment in early and late onset alzheimer's disease. *Journal of Alzheimeris Disease*, **2013**, 35, 169-78	4.3	18
623	Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. *Journal of Alzheimeris Disease*, **2013**, 36, 79-85	4.3	19
622	Improvement of white matter changes on neuroimaging modalities after stem cell transplant in metachromatic leukodystrophy. *JAMA Neurology*, **2013**, 70, 779-82	17.2	34

621	Single-subject grey matter graphs in Alzheimer's disease. *PLoS ONE*, **2013**, 8, e58921	3.7	80
620	Resection probability maps for quality assessment of glioma surgery without brain location bias. *PLoS ONE*, **2013**, 8, e73353	3.7	50
619	Cognitive and clinical dysfunction, altered MEG resting-state networks and thalamic atrophy in multiple sclerosis. *PLoS ONE*, **2013**, 8, e69318	3.7	58
618	Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. *Radiology*, **2013**, 269, 542-52	20.5	48
617	Relationships between white matter hyperintensities, cerebral amyloid angiopathy and dementia in a population-based sample of the oldest old. *Current Alzheimer Research*, **2013**, 10, 1090-7	3	11
616	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. *Lancet Neurology, The*, **2012**, 11, 33-41	24.1	153
615	Association between pathological and MRI findings in multiple sclerosis. *Lancet Neurology, The*, **2012**, 11, 349-60	24.1	267
614	Callosal tissue loss parallels subtle decline in psychomotor speed. a longitudinal quantitative MRI study. The LADIS Study. *Neuropsychologia*, **2012**, 50, 1650-5	3.2	17
613	Diffusion tensor imaging in type 1 diabetes: decreased white matter integrity relates to cognitive functions. *Diabetologia*, **2012**, 55, 1218-20	10.3	42
612	The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. *Journal of Neurology*, **2012**, 259, 147-54	5.5	79
611	EFNS task force: the use of neuroimaging in the diagnosis of dementia. *European Journal of Neurology*, **2012**, 19, e131-40, 1487-501	6	90
610	Subcortical atrophy and cognition: sex effects in multiple sclerosis. *Neurology*, **2012**, 79, 1754-61	6.5	148
609	Diagnostic relevance of high field MRI in clinical neuroradiology: the advantages and challenges of driving a sports car. *European Radiology*, **2012**, 22, 2304-6	8	4
608	Inflammation high-field magnetic resonance imaging. *Neuroimaging Clinics of North America*, **2012**, 22, 135-57, ix	3	21
607	O4-03-01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease **2012**, 8, P618-P618		
606	Microglial activation in healthy aging. *Neurobiology of Aging*, **2012**, 33, 1067-72	5.6	110
605	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 627.e1-627.e12	5.6	58
604	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. *Neurobiology of Aging*, **2012**, 33, 2018-28	5.6	253

603	Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 1011.e1-9	5.6	46
602	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. *Neurobiology of Aging*, **2012**, 33, 2272-81	5.6	72
601	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. *Neurology*, **2012**, 79, 763-9	6.5	62
600	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 1145-8	5.5	17
599	Demyelinating Diseases **2012**, 50-57		
598	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. *BMC Neuroscience*, **2012**, 13, 85	3.2	18
597	Fast eigenvector centrality mapping of voxel-wise connectivity in functional magnetic resonance imaging: implementation, validation, and interpretation. *Brain Connectivity*, **2012**, 2, 265-74	2.7	81
596	Cognitive dysfunction in early multiple sclerosis: altered centrality derived from resting-state functional connectivity using magneto-encephalography. *PLoS ONE*, **2012**, 7, e42087	3.7	45
595	The spatial distribution of age-related white matter changes as a function of vascular risk factors--results from the LADIS study. *NeuroImage*, **2012**, 60, 1597-607	7.9	66
594	Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis. *NeuroImage*, **2012**, 61, 1484-94	7.9	116
593	Neuroplasticity and functional recovery in multiple sclerosis. *Nature Reviews Neurology*, **2012**, 8, 635-46	15	100
592	Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. *Archives of Neurology*, **2012**, 69, 198-207		288
591	Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration. *Journal of Magnetic Resonance Imaging*, **2012**, 36, 1-19	5.6	41
590	Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects. *Human Brain Mapping*, **2012**, 33, 1225-45	5.9	31
589	Resting-state networks in awake five- to eight-year old children. *Human Brain Mapping*, **2012**, 33, 1189-201	5.9	108
588	Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. *Human Brain Mapping*, **2012**, 33, 2268-80	5.9	57
587	Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. *Neurology*, **2012**, 78, 1785-92	6.5	98
586	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 990-1000	8.8	116

585	Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. *European Radiology*, **2012**, 22, 221-31	8	62
584	Making better use of our brain MRI research data. *European Radiology*, **2012**, 22, 1395-6	8	3
583	Characteristics of early MRI in children and adolescents with vanishing white matter. *Neuropediatrics*, **2012**, 43, 22-6	1.6	24
582	Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. *Multiple Sclerosis Journal*, **2012**, 18, 1092-8	5	12
581	Preliminary evidence of hippocampal damage in chronic users of ecstasy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 83-5	5.5	21
580	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. *Neurology*, **2012**, 79, 1809-16	6.5	110
579	Coil-treated aneurysms: decision making regarding additional treatment based on findings of MR angiography and intraarterial DSA. *Radiology*, **2012**, 265, 858-63	20.5	17
578	PS11 - 50. Depressive symptoms exacerbate the negative effects of type 1 diabetes and microangiopathy on brain functioning. *Nederlands Tijdschrift Voor Diabetologie*, **2012**, 10, 133-133	0	
577	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. *Brain*, **2012**, 135, 2115-25	11.2	91
576	Postmortem verification of MS cortical lesion detection with 3D DIR. *Neurology*, **2012**, 78, 302-8	6.5	173
575	Gender-related differences in functional connectivity in multiple sclerosis. *Multiple Sclerosis Journal* , **2012**, 18, 164-73	5	68
574	Resting-state brain networks in type 1 diabetic patients with and without microangiopathy and their relation to cognitive functions and disease variables. *Diabetes*, **2012**, 61, 1814-21	0.9	99
573	A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. *Neurology*, **2012**, 78, 841	6.5	8
572	Novel hypomyelinating leukoencephalopathy affecting early myelinating structures. *Archives of Neurology*, **2012**, 69, 125-8		17
571	The predictive value of 3D time-of-flight MR angiography in assessment of brain arteriovenous malformation obliteration after radiosurgery. *American Journal of Neuroradiology*, **2012**, 33, 232-8	4.4	26
570	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. *Multiple Sclerosis Journal*, **2012**, 18, 1466-71	5	47
569	Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2012**, 18, 1577-84	5	20
568	Reply:. *American Journal of Neuroradiology*, **2012**, 33, E98-E98	4.4	78

567	Restricted diffusion in vanishing white matter. *Archives of Neurology*, **2012**, 69, 723-7		14
566	White matter lesion progression in LADIS: frequency, clinical effects, and sample size calculations. *Stroke*, **2012**, 43, 2643-7	6.7	73
565	Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. *Journal of Alzheimeris Disease*, **2012**, 29, 319-27	4.3	54
564	Novel infantile-onset leukoencephalopathy with high lactate level and slow improvement. *Archives of Neurology*, **2012**, 69, 718-22		8
563	Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. *Journal of Alzheimeris Disease*, **2012**, 29, 459-69	4.3	31
562	Fingolimod Treatment Increases the Proportion of Patients Who Are Free from Disease Activity in Multiple Sclerosis Compared to IFN-b1a: Results from a Phase 3, Active-Controlled Study (TRANSFORMS) (PD5.006). *Neurology*, **2012**, 78, PD5.006-PD5.006	6.5	5
561	Imaging Alzheimer in 2011 **2012**, 217-219		
560	Normal Ageing **2011**, 43-57		5
559	Diffusion magnetic resonance imaging in multiple sclerosis. *Neuroimaging Clinics of North America*, **2011**, 21, 71-88, vii-viii	3	18
558	Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. *Journal of the Neurological Sciences*, **2011**, 311, 44-9	3.2	88
557	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. *Journal of the Neurological Sciences*, **2011**, 307, 100-5	3.2	51
556	Neuroimaging in Dementia **2011**,		60
555	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. *Alzheimeris and Dementia*, **2011**, 7, 474-485.e4	1.2	139
554	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. *Lancet, The*, **2011**, 378, 1779-87	40	522
553	T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 72-7	5.5	41
552	A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. *European Journal of Neuroscience*, **2011**, 33, 1256-63	3.5	21
551	Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. *Psychiatry Research - Neuroimaging*, **2011**, 193, 182-90	2.9	38
550	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. *Lancet Neurology, The*, **2011**, 10, 520-9	24.1	178

549	Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement. *European Radiology*, **2011**, 21, 1526-34	8	40
548	Visual assessment of posterior atrophy development of a MRI rating scale. *European Radiology*, **2011**, 21, 2618-25	8	223
547	Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. *CardioVascular and Interventional Radiology*, **2011**, 34, 1-2	2.7	34
546	Imaging Alzheimer in 2011. *Neuroradiology*, **2011**, 53 Suppl 1, S145-7	3.2	1
545	MRI assessment of iron deposition in multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2011**, 34, 13-21	5.6	67
544	2010 revisions to McDonald criteria for diagnosis of multiple sclerosis: impact of 3-Tesla magnetic resonance imaging. *Annals of Neurology*, **2011**, 70, 182-3	9.4	13
543	Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. *Neurology*, **2011**, 76, 418-24	6.5	212
542	Leucoencephalopathy with brainstem and spinal cord involvement and high lactate: quantitative magnetic resonance imaging. *Brain*, **2011**, 134, 3333-41	11.2	22
541	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 126-35	5.5	430
540	Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. *Stroke*, **2011**, 42, 1894-900	6.7	103
539	No influence of KIF1B on neurodegenerative markers in multiple sclerosis. *Neurology*, **2011**, 76, 1843-5	6.5	2
538	Correlating quantitative MR imaging with histopathology in X-linked adrenoleukodystrophy. *American Journal of Neuroradiology*, **2011**, 32, 481-9	4.4	27
537	Fetal Origin of Brain Damage in 2 Infants with aCOL4A1Mutation: Fetal and Neonatal MRI. *Neuropediatrics*, **2011**, 42, e1-e1	1.6	2
536	Suspected early dementia. *BMJ, The*, **2011**, 343, d5568	5.9	2
535	Fetal origin of brain damage in 2 infants with a COL4A1 mutation: fetal and neonatal MRI. *Neuropediatrics*, **2011**, 42, 1-3	1.6	46
534	Localisation of the central sulcus region in glioma patients with three-dimensional fluid-attenuated inversion recovery and volume rendering: comparison with functional and conventional magnetic resonance. *British Journal of Neurosurgery*, **2011**, 25, 210-7	1	3
533	The changing face of multiple sclerosis clinical trial populations. *Current Medical Research and Opinion*, **2011**, 27, 1529-37	2.5	36
532	Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. *Multiple Sclerosis Journal*, **2011**, 17, 1202-10	5	86

531	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. *Multiple Sclerosis Journal*, **2011**, 17, 319-26	5	8
530	Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. *Multiple Sclerosis Journal*, **2011**, 17, 1098-106	5	139
529	Incident lacunes influence cognitive decline: the LADIS study. *Neurology*, **2011**, 76, 1872-8	6.5	148
528	Modeling MR imaging enhancing-lesion volumes in multiple sclerosis: application in clinical trials. *American Journal of Neuroradiology*, **2011**, 32, 2093-7	4.4	3
527	Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy. *Neurology*, **2011**, 76, S28-37	6.5	25
526	PS1 - 4. Widespread decreased white matter tract integrity in T1DM patients with microangiopathy and its relation to cognitive functions. *Nederlands Tijdschrift Voor Diabetologie*, **2011**, 9, 93-93	0	
525	One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1125-31	5.5	12
524	Corpus callosum tissue loss and development of motor and global cognitive impairment: the LADIS study. *Dementia and Geriatric Cognitive Disorders*, **2011**, 32, 279-86	2.6	20
523	Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. *Neurology*, **2011**, 76, 574-6	6.5	21
522	No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 429-35	5.5	95
521	Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. *Neurology*, **2011**, 77, 835-43	6.5	37
520	Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study. *American Journal of Neuroradiology*, **2011**, 32, 695-703	4.4	8
519	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. *Nature Reviews Neurology*, **2011**, 8, 13-21	15	57
518	Global and regional differences in brain anatomy of young children born small for gestational age. *PLoS ONE*, **2011**, 6, e24116	3.7	43
517	White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients. *Journal of Clinical Psychiatry*, **2011**, 72, 104-12	4.6	36
516	Disorders Mainly Affecting White Matter **2011**, 177-242		1
515	Dementia: Clinical Background **2011**, 5-11		
514	Primary Grey Matter Loss **2011**, 59-135		

513	Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. *Neurology*, **2010**, 75, 1617-22	6.5	50
512	Performance of the Swanton multiple sclerosis criteria for dissemination in space. *Multiple Sclerosis Journal*, **2010**, 16, 985-7	5	9
511	Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings. *Alzheimer Disease and Associated Disorders*, **2010**, 24, 303-7	2.5	23
510	Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI. *Alzheimer Disease and Associated Disorders*, **2010**, 24, 242-7	2.5	18
509	Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients. *Dementia and Geriatric Cognitive Disorders*, **2010**, 29, 301-8	2.6	3
508	Cerebrospinal fluid ATP metabolites in multiple sclerosis. *Multiple Sclerosis Journal*, **2010**, 16, 549-54	5	38
507	New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. *Dementia and Geriatric Cognitive Disorders*, **2010**, 30, 1-7	2.6	35
506	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. *Neurology*, **2010**, 74, 1868-76	6.5	234
505	Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. *Neurology*, **2010**, 74, 1954-60	6.5	97
504	Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study. *Stroke*, **2010**, 41, e402-8	6.7	70
503	Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. *Multiple Sclerosis Journal*, **2010**, 16, 325-31	5	12
502	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *New England Journal of Medicine*, **2010**, 362, 402-15	59.2	1686
501	Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 1351-6	5.5	54
500	Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. *Multiple Sclerosis Journal*, **2010**, 16, 660-9	5	34
499	MRI criteria for MS in patients with clinically isolated syndromes. *Neurology*, **2010**, 74, 427-34	6.5	187
498	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 547-51	5.5	82
497	The limits of functional reorganization in multiple sclerosis. *Neurology*, **2010**, 74, 1246-7	6.5	80
496	Resting state networks change in clinically isolated syndrome. *Brain*, **2010**, 133, 1612-21	11.2	194

495	Magnetic resonance imaging pattern recognition in hypomyelinating disorders. *Brain*, **2010**, 133, 2971-82	11.2	210
494	Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. *Neurology*, **2010**, 75, 1228-33	6.5	29
493	Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. *Neurology*, **2010**, 75, 2071-8	6.5	68
492	Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. *American Journal of Neuroradiology*, **2010**, 31, 541-8	4.4	42
491	Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. *Radiology*, **2010**, 255, 154-63	20.5	52
490	Intracranial aneurysms treated with coil placement: test characteristics of follow-up MR angiography--multicenter study. *Radiology*, **2010**, 256, 209-18	20.5	52
489	Structural and functional hippocampal changes in multiple sclerosis patients with intact memory function. *Radiology*, **2010**, 255, 595-604	20.5	95
488	Use of Imaging in Multiple Sclerosis **2010**, 35-51		
487	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. *Neurobiology of Aging*, **2010**, 31, 758-64	5.6	77
486	Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. *PLoS ONE*, **2010**, 5, e13788	3.7	434
485	Combining shape and connectivity analysis: an MRI study of thalamic degeneration in Alzheimer's disease. *NeuroImage*, **2010**, 49, 1-8	7.9	138
484	Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?. *Neurology*, **2010**, 74, 1033-40	6.5	118
483	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 882-4	5.5	47
482	Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. *Annals of Neurology*, **2010**, 67, 667-75	9.4	22
481	Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. *European Radiology*, **2010**, 20, 1675-83	8	121
480	Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. *Neuroradiology*, **2010**, 52, 875-81	3.2	27
479	Chronic cerebrospinal venous insufficiency and multiple sclerosis. *Annals of Neurology*, **2010**, 67, 286-90	9.4	107
478	Intercenter differences in diffusion tensor MRI acquisition. *Journal of Magnetic Resonance Imaging*, **2010**, 31, 1458-68	5.6	66

477	Motor testing at 1 year improves the prediction of motor and mental outcome at 2 years after perinatal hypoxic-ischaemic encephalopathy. *Developmental Medicine and Child Neurology*, **2010**, 52, 54-9	3.3	9
476	Accumulation of cortical lesions in MS: relation with cognitive impairment. *Multiple Sclerosis Journal* , **2009**, 15, 708-14	5	191
475	Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. *Nature Reviews Neurology*, **2009**, 5, 256-66	15	316
474	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2009**, 80, 478-83	5.5	85
473	Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. *Journal of Nuclear Medicine*, **2009**, 50, 191-7	8.9	108
472	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. *Multiple Sclerosis Journal*, **2009**, 15, 1459-65	5	26
471	Grid infrastructures for computational neuroscience: the neuGRID example. *Future Neurology*, **2009** , 4, 703-722	1.5	32
470	Association between MRI parameters and the MS severity scale: a 12 year follow-up study. *Multiple Sclerosis Journal*, **2009**, 15, 632-7	5	29
469	White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2009** , 80, 1069-74	5.5	32
468	Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. *Multiple Sclerosis Journal*, **2009**, 15, 180-8	5	60
467	Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. *Archives of Neurology*, **2009**, 66, 601-9		120
466	Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. *Multiple Sclerosis Journal*, **2009**, 15, 465-71	5	13
465	Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. *Stroke*, **2009**, 40, 773-9	6.7	69
464	Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. *Archives of Neurology*, **2009**, 66, 1345-52		28
463	Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. *BMJ, The*, **2009**, 339, b2477	5.9	277
462	MRI--the perfect surrogate marker for multiple sclerosis?. *Nature Reviews Neurology*, **2009**, 5, 182-3	15	25
461	Quantitative MR Imaging and Spectroscopy in CongenitalCytomegalovirusInfection and Periventricular Leukomalacia Suggests a Comparable Neuropathological Substrate of the Cerebral White Matter Lesions. *Neuropediatrics*, **2009**, 40, 173-173	1.6	6
460	Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. *Radiology*, **2009**, 250, 506-14	14.5	41

459	Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. *Radiology*, **2009**, 253, 174-83	20.5	97
458	MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. *Stroke*, **2009**, 40, 492-8	6.7	99
457	The clinical profile of right temporal lobe atrophy. *Brain*, **2009**, 132, 1287-98	11.2	220
456	Quantitative MR imaging and spectroscopy in congenital cytomegalovirus infection and periventricular leukomalacia suggests a comparable neuropathological substrate of the cerebral white matter lesions. *Neuropediatrics*, **2009**, 40, 168-73	1.6	22
455	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. *Neurology*, **2009**, 73, 935-40	6.5	59
454	MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. *Neurology*, **2009**, 72, 1693-701	6.5	43
453	Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. *Neurology*, **2009**, 72, 999-1007	6.5	238
452	Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. *Neurology*, **2009**, 72, 595-601	6.5	81
451	The distribution of new enhancing lesion counts in multiple sclerosis: further explorations. *Multiple Sclerosis Journal*, **2009**, 15, 42-9	5	32
450	MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. *BMC Neurology*, **2009**, 9, 19	3.1	15
449	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurology, The*, **2009**, 8, 987-97	24.1	279
448	Model-free group analysis shows altered BOLD FMRI networks in dementia. *Human Brain Mapping*, **2009**, 30, 256-66	5.9	107
447	White matter tract integrity in aging and Alzheimer's disease. *Human Brain Mapping*, **2009**, 30, 1051-9	5.9	194
446	Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. *Human Brain Mapping*, **2009**, 30, 2412-25	5.9	47
445	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: the LADIS (Leukoaraiosis and Disability in the Elderly) study. *Journal of Magnetic Resonance Imaging*, **2009**, 29, 268-74	5.6	30
444	Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. *Journal of Magnetic Resonance Imaging*, **2009**, 29, 774-9	5.6	39
443	Clinical correlations of brain lesion distribution in multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2009**, 29, 768-73	5.6	56
442	High field MRI in the diagnosis of multiple sclerosis: high field-high yield?. *Neuroradiology*, **2009**, 51, 279-92	3.2	63

441	Unraveling pathology in juvenile Alexander disease: serial quantitative MR imaging and spectroscopy of white matter. *Neuroradiology*, **2009**, 51, 669-75	3.2	25
440	Translating pathology in multiple sclerosis: the combination of postmortem imaging, histopathology and clinical findings. *Acta Neurologica Scandinavica*, **2009**, 119, 349-55	3.8	33
439	A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. *European Radiology*, **2009**, 19, 2244-8	8	5
438	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. *European Radiology*, **2009**, 19, 2826-33	8	74
437	Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. *Stroke*, **2009**, 40, 3455-60	6.7	179
436	Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. *Stroke*, **2009**, 40, 1269-74	6.7	112
435	Segmental muscular atrophy of the distal upper extremity (Hirayama disease): An atypical case with anterior dural detachment. *European Journal of Radiology Extra*, **2009**, 72, e53-e55		1
434	Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. *Neuroimaging Clinics of North America*, **2009**, 19, 81-99	3	51
433	MRI-defined subcortical ischemic vascular disease: baseline clinical and neuropsychological findings. The LADIS Study. *Cerebrovascular Diseases*, **2009**, 27, 336-44	3.2	70
432	Longitudinal cognitive decline in subcortical ischemic vascular disease--the LADIS Study. *Cerebrovascular Diseases*, **2009**, 27, 384-91	3.2	139
431	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. *Human Molecular Genetics*, **2009**, 18, 767-78	5.6	357
430	Regional DTI differences in multiple sclerosis patients. *NeuroImage*, **2009**, 44, 1397-403	7.9	296
429	Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosis. *NeuroImage*, **2009**, 45, 500-11	7.9	33
428	HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. *Archives of Neurology*, **2009**, 66, 1531-6		26
427	Multi-Contrast, Isotropic, Single-Slab 3D MR Imaging in Multiple Sclerosis. *Neuroradiology Journal*, **2009**, 22, 33-42	2	2
426	5 Beeldvormend onderzoek **2009**, 43-51		
425	Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. *European Journal of Neurology*, **2008**, 15, 113-22	6	61
424	Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. *European Journal of Pharmacology*, **2008**, 585, 88-96	5.3	81

423	MRI in multiple sclerosis: current status and future prospects. *Lancet Neurology, The*, **2008**, 7, 615-25	24.1	262
422	Grey matter pathology in multiple sclerosis. *Lancet Neurology, The*, **2008**, 7, 841-51	24.1	368
421	Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. *Lancet Neurology, The*, **2008**, 7, 903-14	24.1	386
420	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. *Current Medical Research and Opinion*, **2008**, 24, 2561-74	2.5	106
419	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. *Neurobiology of Aging*, **2008**, 29, 669-75	5.6	87
418	Reduced resting-state brain activity in the "default network" in normal aging. *Cerebral Cortex*, **2008**, 18, 1856-64	5.1	885
417	Segmentation of age-related white matter changes in a clinical multi-center study. *NeuroImage*, **2008**, 41, 335-45	7.9	45
416	Reproducibility of fMRI in the clinical setting: implications for trial designs. *NeuroImage*, **2008**, 42, 603-10	7.9	45
415	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. *Alzheimeris and Dementia*, **2008**, 4, 255-64	1.2	35
414	Feature extraction and strategy of analyzing structural neuroimaging in dementia. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2008**, 89, 75-86	3	1
413	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. *Brain*, **2008**, 131, 3286-98	11.2	195
412	Tumor-volume changes after radiosurgery for vestibular schwannoma: implications for follow-up MR imaging protocol. *American Journal of Neuroradiology*, **2008**, 29, 906-10	4.4	63
411	Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression. *Cerebrovascular Diseases*, **2008**, 25, 247-53	3.2	64
410	At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only. *Multiple Sclerosis Journal*, **2008**, 14, 428-30	5	4
409	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 455-64	5	46
408	Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. *Brain*, **2008**, 131, 800-7	11.2	148
407	Neurological signs in relation to type of cerebrovascular disease in vascular dementia. *Stroke*, **2008**, 39, 317-22	6.7	60
406	Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. *Stroke*, **2008**, 39, 1414-20	6.7	299

405	Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. *Neurology*, **2008**, 70, 1134-40	6.5	52
404	Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities. *American Journal of Neuroradiology*, **2008**, 29, 1296-301	4.4	62
403	Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. *Neurology*, **2008**, 70, 1150-1	6.5	132
402	Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. *Neurology*, **2008**, 70, 1836-41	6.5	76
401	White matter changes contribute to corpus callosum atrophy in the elderly: the LADIS study. *American Journal of Neuroradiology*, **2008**, 29, 1498-504	4.4	43
400	Segmentation of subtraction images for the measurement of lesion change in multiple sclerosis. *American Journal of Neuroradiology*, **2008**, 29, 340-6	4.4	25
399	Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. *American Journal of Neuroradiology*, **2008**, 29, 944-9	4.4	133
398	Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 764-9	5	34
397	Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. *Radiology*, **2008**, 248, 590-8	20.5	107
396	Diffusion-weighted and conventional MR imaging in neonatal hypoxic ischemia: two-year follow-up study. *Radiology*, **2008**, 249, 631-9	20.5	51
395	Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. *Journal of Neurology, Neurosurgery and Psychiatry*, **2008**, 79, 917-23	5.5	36
394	On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. *Stroke*, **2008**, 39, 3083-5	6.7	65
393	Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. *Experimental Brain Research*, **2008**, 187, 25-31	2.3	46
392	Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. *Journal of Neurology*, **2008**, 255, 480-7	5.5	58
391	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. *Journal of Neurology*, **2008**, 255, 1-10	5.5	63
390	Does high-field MR imaging improve cortical lesion detection in multiple sclerosis?. *Journal of Neurology*, **2008**, 255, 183-91	5.5	59
389	A three-year, multi-parametric MRI study in patients at presentation with CIS. *Journal of Neurology*, **2008**, 255, 683-91	5.5	65
388	Does high field MRI allow an earlier diagnosis of multiple sclerosis?. *Journal of Neurology*, **2008**, 255, 1159-63	5.5	50

387	Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. *Journal of Neurology*, **2008**, 255, 1302-8	5.5	75
386	Small vessel versus large vessel vascular dementia: risk factors and MRI findings. *Journal of Neurology*, **2008**, 255, 1644-51; discussion 1813-4	5.5	47
385	In vivo MR imaging of hippocampal lesions in multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2008**, 27, 726-31	5.6	76
384	Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. *Journal of Magnetic Resonance Imaging*, **2008**, 28, 559-65	5.6	18
383	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. *International Journal of Geriatric Psychiatry*, **2008**, 23, 387-92	3.9	24
382	Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. *Annals of Neurology*, **2008**, 63, 790-3	9.4	83
381	Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. *European Radiology*, **2008**, 18, 2311-20	8	77
380	Lack of association between antimyelin antibodies and progression to multiple sclerosis. *New England Journal of Medicine*, **2007**, 356, 371-8	59.2	197
379	Whole brain analysis of T2* weighted baseline FMRI signal in dementia. *Human Brain Mapping*, **2007** , 28, 1313-7	5.9	27
378	Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. *Journal of Magnetic Resonance Imaging*, **2007**, 26, 881-5	5.6	39
377	Delineation of brain AVMs on MR-Angiography for the purpose of stereotactic radiosurgery. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 308-16	4	16
376	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. *Diabetic Medicine*, **2007**, 24, 166-71	3.5	80
375	Association between vitamin B6 and white matter hyperintensities in patients with Alzheimer's disease not mediated by homocysteine metabolism. *Journal of the American Geriatrics Society*, **2007** , 55, 956-8	5.6	9
374	Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS. *Journal of Neuroimmunology*, **2007**, 186, 150-5	3.5	17
373	CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. *Journal of Neuroimmunology*, **2007**, 190, 157-64	3.5	42
372	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. *Lancet Neurology, The*, **2007**, 6, 677-86	24.1	246
371	Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. *Annals of the New York Academy of Sciences*, **2007**, 1097, 215-24	6.5	22
370	Microvasculaire schade en cognitieve achteruitgang bij type-1-diabetes. *Neuropraxis*, **2007**, 11, 32-37	0	1

369	Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. *European Radiology*, **2007**, 17, 67-71	8	10
368	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. *Neuroradiology*, **2007**, 49, 967-76	3.2	209
367	Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. *Diabetologia*, **2007**, 50, 1763-9	10.3	88
366	N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. *Journal of Neurology*, **2007**, 254, 631-7	5.5	29
365	Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 491-6	5.5	76
364	Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. *Multiple Sclerosis Journal*, **2007**, 13, 708-16	5	40
363	Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. *Archives of Internal Medicine*, **2007**, 167, 81-8		154
362	Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. *Annals of Oncology*, **2007**, 18, 1747-50	10.3	31
361	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. *Neurology*, **2007**, 69, 1491-7	6.5	70
360	The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. *Neurology*, **2007**, 69, 1521-7	6.5	138
359	The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. *Stroke*, **2007**, 38, 3182-5	6.7	88
358	Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. *Archives of Neurology*, **2007**, 64, 1292-8		41
357	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*, **2007**, 68, 1163; author reply 1163-4	6.5	9
356	Motor outcome at the age of one after perinatal hypoxic-ischemic encephalopathy. *Neuropediatrics*, **2007**, 38, 71-7	1.6	18
355	Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. *Archives of Neurology*, **2007**, 64, 76-80		116
354	Magnetic resonance imaging predictors of cognition in mild cognitive impairment. *Archives of Neurology*, **2007**, 64, 1023-8		55
353	Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results. *Multiple Sclerosis Journal*, **2007**, 13, 717-21	5	5
352	Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study. *Dementia and Geriatric Cognitive Disorders*, **2007**, 24, 73-81	2.6	33

351	Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. *European Neurology*, **2007**, 58, 90-5	2.1	22
350	Nonlinear changes in brain activity during continuous word repetition: an event-related multiparametric functional MR imaging study. *American Journal of Neuroradiology*, **2007**, 28, 1715-21	4.4	8
349	Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. *Archives of Neurology*, **2007**, 64, 190-4		23
348	Extensive hippocampal demyelination in multiple sclerosis. *Journal of Neuropathology and Experimental Neurology*, **2007**, 66, 819-27	3.1	203
347	Clinical significance of corpus callosum atrophy in a mixed elderly population. *Neurobiology of Aging* , **2007**, 28, 955-63	5.6	58
346	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. *Neurobiology of Aging*, **2007**, 28, 1070-4	5.6	139
345	Endogenous cortisol level interacts with noradrenergic activation in the human amygdala. *Neurobiology of Learning and Memory*, **2007**, 87, 57-66	3.1	134
344	Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. *Clinical Neurophysiology*, **2007**, 118, 1332-40	4.3	33
343	Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. *NeuroImage*, **2007**, 34, 1036-41	7.9	35
342	Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. *NeuroImage*, **2007**, 38, 529-37	7.9	34
341	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. *Lancet, The*, **2007**, 370, 389-97	40	417
340	Thallium-201 SPECT: the optimal prediction of response in glioma therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 222-7	8.8	9
339	Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. *Diabetologia*, **2006**, 49, 2474-80	10.3	137
338	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. *Lancet Neurology, The*, **2006**, 5, 221-7	24.1	94
337	MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". *Lancet Neurology, The*, **2006**, 5, 841-52	24.1	194
336	Corpus callosum size correlates with asymmetric performance on a dichotic listening task in healthy aging but not in Alzheimer's disease. *Neuropsychologia*, **2006**, 44, 208-17	3.2	58
335	Diagnostic tools for the study of vascular cognitive dysfunction in hypertension and antihypertensive drug research **2006**, 109, 274-83		14
334	MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. *Magnetic Resonance in Medicine*, **2006**, 55, 478-83	4.4	111

333	Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. *Journal of Magnetic Resonance Imaging*, **2006**, 23, 628-36	5.6	123
332	Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. *Annals of Neurology* , **2006**, 59, 504-11	9.4	124
331	Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study. *Brain*, **2006**, 129, 141-57	11.2	96
330	The role of spinal cord imaging in the diagnosis of multiple sclerosis. *Nature Clinical Practice Neurology*, **2006**, 2, 283-6; quiz 287		2
329	Infratentorial abnormalities in vascular dementia. *Stroke*, **2006**, 37, 105-10	6.7	27
328	Childhood white matter disorders: quantitative MR imaging and spectroscopy. *Radiology*, **2006**, 241, 510-7	20.5	71
327	Human gray matter: feasibility of single-slab 3D double inversion-recovery high-spatial-resolution MR imaging. *Radiology*, **2006**, 241, 873-9	20.5	78
326	Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. *Radiology*, **2006**, 240, 811-20	20.5	136
325	Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. *Neuropsychopharmacology*, **2006**, 31, 1508-18	8.7	35
324	Prevalence and severity of microbleeds in a memory clinic setting. *Neurology*, **2006**, 66, 1356-60	6.5	238
323	MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. *Neurology*, **2006**, 66, 1384-9	6.5	152
322	Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. *Stroke*, **2006**, 37, 836-40	6.7	236
321	Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. *New England Journal of Medicine*, **2006**, 354, 924-33	59.2	653
320	Microvascular disease in type 1 diabetes alters brain activation: a functional magnetic resonance imaging study. *Diabetes*, **2006**, 55, 334-40	0.9	58
319	Classification of multiple sclerosis patients by latent class analysis of magnetic resonance imaging characteristics. *Multiple Sclerosis Journal*, **2006**, 12, 565-72	5	11
318	Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. *Multiple Sclerosis Journal*, **2006**, 12, 760-8	5	49
317	CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 246-8	5.5	8
316	Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. *Archives of Neurology*, **2006**, 63, 614-9		73

315	Hippocampal atrophy in Alzheimer disease: age matters. *Neurology*, **2006**, 66, 236-8	6.5	100
314	Is the whole brain periventricular?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 143-4	5.5	22
313	Asymptomatic carotid artery stenosis: past, present and future. How to improve patient selection?. *European Neurology*, **2006**, 56, 139-54	2.1	22
312	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 439-42	5.5	119
311	Consistent resting-state networks across healthy subjects. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 13848-53	11.5	3210
310	Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI. *NeuroImage*, **2006**, 32, 1205-15	7.9	94
309	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*, **2006**, 67, 1242-9	6.5	601
308	White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. *Stroke*, **2006**, 37, 2248-52	6.7	40
307	EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. *European Journal of Neurology*, **2006**, 13, 313-25	6	53
306	Leukoaraiosis predicts hidden global functioning impairment in nondisabled older people: the LADIS (Leukoaraiosis and Disability in the Elderly) Study. *Journal of the American Geriatrics Society*, **2006**, 54, 1095-101	5.6	76
305	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. *Neuropathology and Applied Neurobiology*, **2006**, 32, 318-31	5.2	19
304	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. *Journal of Neurology*, **2006**, 253, 1189-96	5.5	101
303	Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 304-7	5.5	73
302	Cerebral white matter abnormalities in 6p25 deletion syndrome. *American Journal of Neuroradiology*, **2006**, 27, 586-8	4.4	16
301	Hippocampal sulcus width and cavities: comparison between patients with Alzheimer disease and nondemented elderly subjects. *American Journal of Neuroradiology*, **2006**, 27, 2141-5	4.4	36
300	Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. *American Journal of Neuroradiology*, **2006**, 27, 2005-11	4.4	49
299	Voxel-based analysis of quantitative T1 maps demonstrates that multiple sclerosis acts throughout the normal-appearing white matter. *American Journal of Neuroradiology*, **2006**, 27, 868-74	4.4	25
298	Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. *American Journal of Neuroradiology*, **2006**, 27, 455-61	4.4	194

297	Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. *Journal of Nutrition, Health and Aging*, **2006**, 10, 123-8; discussion 129-30	5.2	5
296	Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. *Stroke*, **2005**, 36, 2116-20	6.7	266
295	Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. *NeuroImage*, **2005**, 24, 898-909	7.9	164
294	Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. *NeuroImage*, **2005**, 25, 63-75	7.9	33
293	Changes in brain electrical activity during extended continuous word recognition. *NeuroImage*, **2005**, 26, 952-9	7.9	61
292	Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. *NeuroImage*, **2005**, 26, 1078-85	7.9	112
291	Progression of cerebral white matter lesions in Alzheimer's disease: a new window for therapy?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 1286-8	5.5	31
290	Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. *Neurobiology of Disease*, **2005**, 20, 953-60	7.5	143
289	Assessing Treatment Effects on Axonal Loss - Evidence from MRI Monitored Clinical Trials. *The Neuroradiology Journal*, **2005**, 18, 486-492		
288	Detection of root avulsion in the dominant C7 obstetric brachial plexus lesion: experience with three-dimensional constructive interference in steady-state magnetic resonance imaging and electrophysiology. *Neurosurgery*, **2005**, 57, 930-40; discussion 930-40	3.2	20
287	Low vitamin B6 levels are associated with white matter lesions in Alzheimer's disease. *Journal of the American Geriatrics Society*, **2005**, 53, 1073-4	5.6	19
286	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. *Lancet Neurology, The*, **2005**, 4, 281-8	24.1	436
285	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. *Lancet Neurology, The*, **2005**, 4, 341-8	24.1	112
284	Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. *Journal of Neuroimmunology*, **2005**, 158, 222-30	3.5	14
283	Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. *Human Brain Mapping*, **2005**, 26, 231-9	5.9	589
282	Unusual variants of Alexander's disease. *Annals of Neurology*, **2005**, 57, 327-38	9.4	94
281	How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis. *Annals of Neurology*, **2005**, 57, 606-7	9.4	10
280	Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. *Annals of Neurology*, **2005**, 58, 781-3	9.4	53

279	Assessment and correction of B1-induced errors in magnetization transfer ratio measurements. *Magnetic Resonance in Medicine*, **2005**, 53, 134-40	4.4	49
278	MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. *Magnetic Resonance in Medicine*, **2005**, 53, 256-66	4.4	122
277	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 1497-500	5.5	71
276	Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. *Neurology*, **2005**, 65, 633-5	6.5	52
275	Frontal-striatal dysfunction during planning in obsessive-compulsive disorder. *Archives of General Psychiatry*, **2005**, 62, 301-9		300
274	Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. *Neurology*, **2005**, 64, 987-91	6.5	211
273	Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. *Neurology*, **2005**, 65, 56-61	6.5	41
272	NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. *Neurology*, **2005**, 65, 1341	6.5	
271	Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. *Neurology*, **2005**, 65, 1447-54	6.5	40
270	Retinoblastoma: MR imaging parameters in detection of tumor extent. *Radiology*, **2005**, 235, 197-207	20.5	86
269	Neurophysiological correlates of increased verbal working memory in high-dissociative participants: a functional MRI study. *Psychological Medicine*, **2005**, 35, 175-85	6.9	47
268	Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. *Radiology*, **2005**, 236, 254-60	20.5	400
267	Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. *Multiple Sclerosis Journal*, **2005**, 11, 524-31	5	108
266	Blood pressure, white matter lesions and medial temporal lobe atrophy: closing the gap between vascular pathology and Alzheimer's disease?. *Dementia and Geriatric Cognitive Disorders*, **2005**, 20, 331-7	2.6	19
265	Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. *American Journal of Neuroradiology*, **2005**, 26, 442-6	4.4	54
264	Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. *American Journal of Neuroradiology*, **2005**, 26, 572-7	4.4	270
263	Bacillus cereus meningoencephalitis in preterm infants: neuroimaging characteristics. *American Journal of Neuroradiology*, **2005**, 26, 2137-43	4.4	26
262	Pattern of white matter abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link pattern with congenital cytomegalovirus infection. *Radiology*, **2004**, 230, 529-36	20.5	142

261	The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. *Radiology*, **2004**, 233, 531-40	20.5	117
260	No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. *Multiple Sclerosis Journal*, **2004**, 10, 272-7	5	29
259	An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. *Multiple Sclerosis Journal*, **2004**, 10, 549-55	5	52
258	Thalamic lesions in vascular dementia: low sensitivity of fluid-attenuated inversion recovery (FLAIR) imaging. *Stroke*, **2004**, 35, 415-9	6.7	41
257	White matter lesions and hippocampal atrophy in Alzheimer's disease. *Neurology*, **2004**, 62, 310-2	6.5	96
256	Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. *Neurology*, **2004**, 62, 1533-9	6.5	149
255	White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. *Neurology*, **2004**, 63, 139-44	6.5	150
254	Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis. *Neuropathology and Applied Neurobiology*, **2004**, 30, 106-17	5.2	55
253	Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels. *Journal of Neuroimmunology*, **2004**, 148, 172-7	3.5	9
252	Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. *Journal of Neuroimmunology*, **2004**, 155, 155-60	3.5	69
251	Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis. *International Journal of Immunogenetics*, **2004**, 31, 133-40		16
250	Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials. *Journal of Neurology*, **2004**, 251 Suppl 4, IV6-12	5.5	7
249	Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility. *Journal of Magnetic Resonance Imaging*, **2004**, 20, 366-71	5.6	57
248	Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. *Neurology*, **2004**, 62, 226-33	6.5	234
247	MRI and CT in the diagnosis of vascular dementia. *Journal of the Neurological Sciences*, **2004**, 226, 9-12	3.2	52
246	Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. *Multiple Sclerosis Journal*, **2004**, 10, 41-6	5	55
245	Interindividual differences of medial temporal lobe activation during encoding in an elderly population studied by fMRI. *NeuroImage*, **2004**, 21, 173-80	7.9	31
244	Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. *NeuroImage* , **2004**, 23, 708-16	7.9	449

243	Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. *NeuroImage*, **2004**, 23, 1450-9	7.9	92
242	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2004**, 364, 1489-96	40	215
241	Pathological aging of the brain: an overview. *Topics in Magnetic Resonance Imaging*, **2004**, 15, 369-89	2.3	48
240	Association of APOE polymorphisms with disease severity in MS is limited to women. *Neurology*, **2004**, 63, 1139; author reply 1139	6.5	2
239	The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee. *Neurology*, **2004**, 63, 1140; author reply 1140	6.5	3
238	Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: a Phase I/II Study with Riluzole **2004**, 41-47		
237	Gender-Related Association Between the TGFB1+869 Polymorphism and Multiple Sclerosis. *Journal of Interferon and Cytokine Research*, **2004**, 24, 536-542	3.5	9
236	The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. *Neurology*, **2003**, 60, 853-60	6.5	76
235	Interobserver variability in the radiological assessment of response to chemotherapy in glioma. *Neurology*, **2003**, 60, 826-30	6.5	79
234	Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. *Neurology*, **2003**, 60, 219-23	6.5	111
233	Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. *Stroke*, **2003**, 34, 1907-12	6.7	122
232	Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. *Neurology*, **2003**, 60, 1904-8	6.5	65
231	Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. *Archives of Neurology*, **2003**, 60, 1073-81		274
230	Diffusion-weighted MRI in severe neonatal hypoxic ischaemia: the white cerebrum. *Neuropediatrics*, **2003**, 34, 72-6	1.6	50
229	Guidelines for brain imaging in vascular dementia clinical trials. *International Psychogeriatrics*, **2003**, 15 Suppl 1, 273-6	3.4	5
228	White-matter changes on MRI as surrogate marker. *International Psychogeriatrics*, **2003**, 15 Suppl 1, 261-5	3.4	9
227	Prenatal diagnosis of aneurysms of the vein of Galen (vena magna cerebri) with conventional sonography, three-dimensional sonography, and magnetic resonance imaging: report of 2 cases. *Journal of Ultrasound in Medicine*, **2003**, 22, 1363-8	2.9	12
226	Spinal-cord MRI in multiple sclerosis. *Lancet Neurology, The*, **2003**, 2, 555-62	24.1	181

225	The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. *Journal of Neuroimmunology*, **2003**, 138, 123-31	3.5	16
224	CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis. *Journal of Neuroimmunology*, **2003**, 140, 188-93	3.5	37
223	Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS. *Journal of Neuroimmunology*, **2003**, 142, 141-8	3.5	31
222	Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2003**, 17, 389-97	5.6	61
221	Multislice T1 relaxation time measurements in the brain using IR-EPI: reproducibility, normal values, and histogram analysis in patients with multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2003**, 18, 656-64	5.6	36
220	A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. *Annals of Neurology*, **2003**, 53, 252-8	9.4	128
219	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. *Annals of Neurology*, **2003**, 53, 718-24	9.4	96
218	Differences between subgroups of MS: MRI findings and correlation with histopathology. *Journal of the Neurological Sciences*, **2003**, 206, 173-4	3.2	12
217	A paced visual serial addition test for fMRI. *Journal of the Neurological Sciences*, **2003**, 213, 29-34	3.2	63
216	Magnetic source imaging contributes to the presurgical identification of sensorimotor cortex in patients with frontal lobe epilepsy. *Clinical Neurophysiology*, **2003**, 114, 221-32	4.3	28
215	Frontostriatal system in planning complexity: a parametric functional magnetic resonance version of Tower of London task. *NeuroImage*, **2003**, 18, 367-74	7.9	185
214	A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. *NeuroImage*, **2003**, 18, 895-907	7.9	347
213	Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. *Stroke*, **2003**, 34, 441-5	6.7	240
212	The interleukin-1 gene family in multiple sclerosis susceptibility and disease course. *Multiple Sclerosis Journal*, **2003**, 9, 535-9	5	18
211	Identifying confounds to increase specificity during a "no task condition". Evidence for hippocampal connectivity using fMRI. *NeuroImage*, **2003**, 20, 1236-45	7.9	75
210	Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. *Multiple Sclerosis Journal*, **2003**, 9, 342-8	5	35
209	[Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype. *Neurology*, **2003**, 61, 1245-8	8.5	20
208	Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. *Journal of Clinical Oncology*, **2003**, 21, 3559-65	2.2	40

207	The FAS-670 polymorphism influences susceptibility to multiple sclerosis. *Journal of Neuroimmunology*, **2002**, 128, 95-100	3.5	28
206	Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. *Journal of Neuroimmunology*, **2002**, 133, 225-32	3.5	34
205	Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. *Lancet Neurology, The*, **2002**, 1, 13-21	24.1	279
204	Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. *Annals of Neurology*, **2002**, 51, 467-74	9.4	22
203	Diffuse signal abnormalities in the spinal cord in multiple sclerosis: direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology. *Annals of Neurology*, **2002**, 51, 652-6	9.4	53
202	Magnetic resonance image registration in multiple sclerosis: comparison with repositioning error and observer-based variability. *Journal of Magnetic Resonance Imaging*, **2002**, 15, 505-10	5.6	9
201	Determination of individual stimulus--response curves in the visual cortex. *Human Brain Mapping*, **2002**, 17, 244-50	5.9	20
200	Image registration and subtraction to detect active T(2) lesions in MS: an interobserver study. *Journal of Neurology*, **2002**, 249, 767-73	5.5	42
199	Whole-brain T1-relaxation time measurements in multiple sclerosis. *Journal of Neurology*, **2002**, 249, 1451-2	5.5	4
198	Isotropic 3D fast FLAIR imaging of the brain in multiple sclerosis patients: initial experience. *European Radiology*, **2002**, 12, 559-67	8	39
197	Two-year follow-up study of primary and transitional progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2002**, 8, 108-14	5	38
196	The role of MRI as a surrogate outcome measure in multiple sclerosis. *Multiple Sclerosis Journal*, **2002**, 8, 40-51	5	32
195	CT and MRI rating of white matter lesions. *Cerebrovascular Diseases*, **2002**, 13 Suppl 2, 31-6	3.2	187
194	The role of MRI as a surrogate outcome measure in multiple sclerosis. *Multiple Sclerosis Journal*, **2002**, 8, 40-51	5	89
193	Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. *Brain*, **2002**, 125, 1676-95	11.2	422
192	Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. *Archives of Neurology*, **2002**, 59, 1572-6		128
191	Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. *Radiology*, **2002**, 223, 46-56	20.5	130
190	Serial isotropic three-dimensional fast FLAIR imaging: using image registration and subtraction to reveal active multiple sclerosis lesions. *American Journal of Roentgenology*, **2002**, 179, 777-82	5.4	26

189	Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2002**, 73, 665-71	5.5	118
188	Imaging of white matter lesions. *Cerebrovascular Diseases*, **2002**, 13 Suppl 2, 21-30	3.2	104
187	Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. *Multiple Sclerosis Journal*, **2002**, 8, 410-4	5	42
186	The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. *Multiple Sclerosis Journal*, **2002**, 8, 532-3	5	113
185	Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. *Multiple Sclerosis Journal*, **2002**, 8, 415-9	5	44
184	Visual rating scales for age-related white matter changes (leukoaraiosis): can the heterogeneity be reduced?. *Stroke*, **2002**, 33, 2827-33	6.7	90
183	The clinico-radiological paradox in multiple sclerosis revisited. *Current Opinion in Neurology*, **2002**, 15, 239-45	7.1	443
182	Seasonal variation in immune measurements and MRI markers of disease activity in MS. *Neurology*, **2002**, 58, 1077-80	6.5	36
181	Patterns of Cerebral Atrophy in Dementia with Lewy Bodies Using Voxel-Based Morphometry. *NeuroImage*, **2002**, 17, 618-630	7.9	167
180	Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. *Neurology*, **2002**, 59, 1766-71	6.5	127
179	Magnetic Resonance: Applications in Dementia **2002**, 5-25		
178	Neurodegenerative Disorders **2002**, 31-138		
177	Disorders Primarily Affecting White Matter **2002**, 139-230		
176	Magnetic Resonance and Dementia **2002**, 1-4		1
175	Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. *NeuroImage*, **2002**, 17, 618-30	7.9	66
174	Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. *Archives of Neurology*, **2001**, 58, 76-81		96
173	TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS. *Neurology*, **2001**, 57, 1129-31	6.5	18
172	Improved interobserver agreement for visual detection of active T2 lesions on serial MR scans in multiple sclerosis using image registration. *Journal of Neurology*, **2001**, 248, 789-94	5.5	10

171	Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: atypical molecular phenotype. *Annals of Neurology*, **2001**, 50, 258-61	9.4	22
170	Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells. *Journal of Neuroimmunology*, **2001**, 118, 286-94	3.5	22
169	Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. *Journal of Neurology, Neurosurgery and Psychiatry*, **2001**, 70, 494-9	5.5	45
168	Modelling new enhancing MRI lesion counts in multiple sclerosis. *Multiple Sclerosis Journal*, **2001**, 7, 298-304	3	26
167	Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. *Brain*, **2001**, 124, 154-66	11.2	140
166	The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. *Neurology*, **2001**, 57, 2185-90	6.5	60
165	Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. *Neurology*, **2001**, 57, 2191-7	6.5	51
164	T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. *Brain*, **2001**, 124, 1396-402	11.2	65
163	Raloxifene affects brain activation patterns in postmenopausal women during visual encoding. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 1422-4	5.6	31
162	Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. *Neurology*, **2001**, 56, 215-9	6.5	63
161	A new rating scale for age-related white matter changes applicable to MRI and CT. *Stroke*, **2001**, 32, 1318-22	6.7	1270
160	Optimizing the association between disability and biological markers in MS. *Neurology*, **2001**, 57, 1253-8	6.5	113
159	Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. *Brain*, **2001**, 124, 1635-45	11.2	214
158	Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy. *Journal of the Neurological Sciences*, **2001**, 184, 155-62	3.2	74
157	Anterior medial temporal lobe activation during attempted retrieval of encoded visuospatial scenes: an event-related fMRI study. *NeuroImage*, **2001**, 14, 67-76	7.9	59
156	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. *Lancet, The*, **2001**, 357, 1576-82	40	884
155	Modelling new enhancing MRI lesion counts in multiple sclerosis. *Multiple Sclerosis Journal*, **2001**, 7, 298-304	3	6
154	Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disability **2000**, 10, 67-72		38

153	FMRI of visual encoding: reproducibility of activation. *Human Brain Mapping*, **2000**, 9, 156-64	5.9	173
152	Diagnostic criteria for primary progressive multiple sclerosis: A position paper. *Annals of Neurology*, **2000**, 47, 831-835	9.4	313
151	Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. *Hippocampus*, **2000**, 10, 398-410	3.5	282
150	Spinal cord magnetic resonance imaging in suspected multiple sclerosis. *European Radiology*, **2000**, 10, 368-76	8	21
149	Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis. *European Radiology*, **2000**, 10, 753-8	8	38
148	Management of obstetric brachial plexus lesions: state of the art and future developments. *Childis Nervous System*, **2000**, 16, 638-44	1.7	76
147	The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement. *Journal of Neurology*, **2000**, 247, 34-40	5.5	16
146	The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study. *Multiple Sclerosis Journal*, **2000**, 6, 237-40	5	19
145	The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. *Brain*, **2000**, 123 (Pt 11), 2256-63	11.2	214
144	One year follow up study of primary and transitional progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 68, 713-8	5.5	82
143	MS functional composite: relation to disease phenotype and disability strata. *Neurology*, **2000**, 54, 1233-8	8.5	81
142	Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. *Multiple Sclerosis Journal*, **2000**, 6, 99-104	5	66
141	Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. *Multiple Sclerosis Journal*, **2000**, 6, 280-5	5	79
140	Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. *Neuroscience Letters*, **2000** , 285, 231-3	3.3	129
139	Value of fluid-attenuated inversion recovery sequences in early MRI of the brain in neonates with a perinatal hypoxic-ischemic encephalopathy. *European Radiology*, **2000**, 10, 1594-601	8	12
138	Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. *Radiology*, **2000**, 217, 869-76	20.5	119
137	Assessment of spinal cord damage in MS using MRI. *Journal of the Neurological Sciences*, **2000**, 172 Suppl 1, S36-9	3.2	10
136	Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. *Multiple Sclerosis Journal*, **2000**, 6, 99-104	5	3

135	Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. *Multiple Sclerosis Journal*, **2000**, 6, 280-285	5	7
134	MR venography of multiple sclerosis. *American Journal of Neuroradiology*, **2000**, 21, 1039-42	4.4	141
133	Visualizing brain activation during planning: the tower of London test adapted for functional MR imaging. *American Journal of Neuroradiology*, **2000**, 21, 1407-14	4.4	72
132	Functional MR imaging in Alzheimer's disease during memory encoding. *American Journal of Neuroradiology*, **2000**, 21, 1869-75	4.4	141
131	Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways **2000**, 10, 398		9
130	Diagnostic criteria for primary progressive multiple sclerosis: A position paper **2000**, 47, 831		13
129	Diagnostic criteria for primary progressive multiple sclerosis: a position paper. *Annals of Neurology*, **2000**, 47, 831-5	9.4	73
128	T1 hypointensities and axonal loss. *Neuroimaging Clinics of North America*, **2000**, 10, 739-52 ,ix	3	29
127	Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. *Brain*, **1999**, 122 (Pt 8), 1589-95	11.2	55
126	The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. *Neurology*, **1999**, 53, 448-56	6.5	229
125	Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. *Journal of Neurology, Neurosurgery and Psychiatry*, **1999**, 66, 465-9	5.5	17
124	Primary and transitional progressive MS: a clinical and MRI cross-sectional study. *Neurology*, **1999**, 52, 839-45	6.5	148
123	Cortical lesions in multiple sclerosis. *Brain*, **1999**, 122 (Pt 1), 17-26	11.2	644
122	MRI enhancing lesion frequency from patients with MS enrolled in the placebo arms of clinical trials or in natural history studies. *Magnetic Resonance Imaging*, **1999**, 17, 1236-7	3.3	
121	Interobserver agreement for diagnostic MRI criteria in suspected multiple sclerosis. *Neuroradiology*, **1999**, 41, 347-50	3.2	17
120	Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility. *Neuroradiology*, **1999**, 41, 882-8	3.2	52
119	Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. *Journal of Neurology*, **1999**, 246, 920-5	5.5	10
118	Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. *Annals of Neurology*, **1999**, 45, 695-703	9.4	222

117	Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. *Annals of Neurology*, **1999**, 46, 79-87	9.4	169
116	Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. *Annals of Neurology*, **1999**, 46, 747-754	9.4	613
115	Parametric fMRI analysis of visual encoding in the human medial temporal lobe. *Hippocampus*, **1999** , 9, 637-43	3.5	38
114	A multicenter measurement of magnetization transfer ratio in normal white matter. *Journal of Magnetic Resonance Imaging*, **1999**, 9, 441-6	5.6	89
113	MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). *Multiple Sclerosis Journal*, **1999**, 5, 283-6	5	150
112	Magnetic resonance (MR) imaging as a marker for multiple sclerosis. *Biomedicine and Pharmacotherapy*, **1999**, 53, 351-7	7.5	6
111	Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. *Lancet, The*, **1999**, 353, 964-9	40	413
110	Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. *Metabolism: Clinical and Experimental*, **1999**, 48, 233-8	12.7	75
109	Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **1999**, 354, 1675-86	5.8	73
108	Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. *Journal of the Neurological Sciences*, **1999**, 163, 74-80	3.2	65
107	Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. *Archives of Neurology*, **1999**, 56, 345-51		53
106	MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). *Multiple Sclerosis Journal*, **1999**, 5, 283-286	5	12
105	Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography. *Annals of Surgery*, **1999**, 230, 31-7	7.8	125
104	Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. *Annals of Neurology*, **1999**, 46, 79-87	9.4	47
103	Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. *Annals of Neurology*, **1999**, 46, 747-54	9.4	211
102	Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. *Annals of Neurology*, **1998**, 43, 332-9	9.4	142
101	Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. *Annals of Neurology*, **1998**, 43, 499-506	9.4	120
100	Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study. *Journal of Neurology*, **1998**, 245, 153-8	5.5	63

99	Within-subject reproducibility of visual activation patterns with functional magnetic resonance imaging using multislice echo planar imaging. *Magnetic Resonance Imaging*, **1998**, 16, 105-13	3.3	145
98	Magnetization transfer contrast (MTC) and long repetition time spin-echo MR imaging in multiple sclerosis. *Magnetic Resonance Imaging*, **1998**, 16, 351-8	3.3	9
97	Methylprednisolone for Acute Relapses of Multiple Sclerosis. *CNS Drugs*, **1998**, 10, 233-238	6.7	1
96	Choosing drug therapy for multiple sclerosis. An update. *Drugs*, **1998**, 56, 555-69	12.1	12
95	Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. *Journal of the Neurological Sciences*, **1998**, 160, 164-70	3.2	141
94	Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. *Neurology*, **1998**, 50, 1282-8	6.5	557
93	Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. *Journal of Neurology, Neurosurgery and Psychiatry*, **1998**, 64, 50-5	5.5	30
92	White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. *European Neurology*, **1998**, 39, 80-9	2.1	208
91	Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. *Neurology*, **1998**, 50, 238-44	6.5	77
90	Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis. *Archives of Neurology*, **1998**, 55, 793-8		53
89	Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study. *European Neurology*, **1998**, 40, 91-8	2.1	26
88	Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. *Brain*, **1998**, 121 (Pt 4), 687-97	11.2	256
87	Visual activation patterns in patients with optic neuritis: an fMRI pilot study. *Neurology*, **1998**, 50, 1896-9	6.5	70
86	Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. *Brain*, **1998**, 121 (Pt 2), 225-31	11.2	36
85	Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. *American Journal of Neuroradiology*, **1998**, 19, 675-83	4.4	173
84	MR outcome parameters in multiple sclerosis: comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a preliminary note). *American Journal of Neuroradiology*, **1998**, 19, 1857-62	4.4	11
83	Sagittal MR of multiple sclerosis in the spinal cord: fast versus conventional spin-echo imaging. *American Journal of Neuroradiology*, **1998**, 19, 355-60	4.4	28
82	Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. *Journal of Neurology, Neurosurgery and Psychiatry*, **1998**, 64 Suppl 1, S77-9	5.5	12

81	Severe irreversible optic neuritis following Mantoux tuberculin skin test in a child with multiple sclerosis--a case report. *Neuropediatrics*, **1997**, 28, 338-40	1.6	4
80	Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. *Neurology*, **1997**, 49, 1682-8	6.5	98
79	Imaging of remyelination. *Multiple Sclerosis Journal*, **1997**, 3, 129-32	5	17
78	Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. *Neurology*, **1997**, 49, 351-7	6.5	205
77	Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis. *Multiple Sclerosis Journal*, **1997**, 3, 226-30	5	15
76	The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population. *Alzheimer Disease and Associated Disorders*, **1997**, 11, 63-70	2.5	44
75	Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. *European Neurology*, **1997**, 37, 95-9	2.1	148
74	Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials. *Neurology*, **1997**, 49, 371-7	6.5	67
73	Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. *Brain*, **1997**, 120 (Pt 11), 2059-69	11.2	832
72	Oral or intravenous methylprednisolone for acute relapses of MS?. *Lancet, The*, **1997**, 349, 893-4	40	14
71	Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials. *Multiple Sclerosis Journal*, **1997**, 2, 283-90	5	19
70	MR imaging in retinoblastoma. *European Radiology*, **1997**, 7, 726-31	8	31
69	Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. *Journal of Neurology*, **1997**, 244, 76-84	5.5	64
68	Quantitative computer-assisted analysis vs. visual estimation of MR imaging response of brain metastases to radiotherapy. *Magnetic Resonance Imaging*, **1997**, 15, 99-106	3.3	4
67	Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. *Magnetic Resonance Imaging*, **1997**, 15, 155-62	3.3	40
66	Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images. *Annals of Neurology*, **1997**, 42, 982	9.4	2
65	Visual association encoding activates the medial temporal lobe: a functional magnetic resonance imaging study. *Hippocampus*, **1997**, 7, 594-601	3.5	123
64	MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. *American Journal of Neuroradiology*, **1997**, 18, 1041-8	4.4	68

63	Test-retest analysis with functional MR of the activated area in the human visual cortex. *American Journal of Neuroradiology*, **1997**, 18, 1317-22	4.4	93
62	Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. *American Journal of Neuroradiology*, **1997**, 18, 1279-85	4.4	27
61	Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study **1997**, 7, 594		2
60	Normal gyration and sulcation in preterm and term neonates: appearance on MR images. *Radiology*, **1996**, 200, 389-96	20.5	122
59	Comparison of film-screen combination and digital fluorography in gastrointestinal barium examinations in a clinical setting. *European Journal of Radiology*, **1996**, 22, 232-5	4.7	9
58	The functional basis of ocular dominance: functional MRI (fMRI) findings. *Neuroscience Letters*, **1996** , 221, 1-4	3.3	87
57	Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. *European Neurology*, **1996**, 36, 268-72	2.1	284
56	Methylprednisolone treatment in multiple sclerosis: effect of treatment, pharmacokinetics, future. *Multiple Sclerosis Journal*, **1996**, 1, 327-8	5	3
55	Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. *Annals of Neurology*, **1996**, 39, 6-16	9.4	387
54	Disappearance of multiple sclerosis lesions with severely prolonged T1 on images obtained by a FLAIR pulse sequence. *Magnetic Resonance Imaging*, **1996**, 14, 209-13	3.3	10
53	Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. *Neurology*, **1996**, 47, 1469-76	6.5	392
52	Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. *Neurology*, **1996**, 47, 1531-4	6.5	615
51	A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. *Multiple Sclerosis Journal*, **1996**, 1, 339-42	5	22
50	Comparison of two MR sequences for the detection of multiple sclerosis lesions in the spinal cord. *American Journal of Neuroradiology*, **1996**, 17, 1533-8	4.4	12
49	Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine. *Multiple Sclerosis Journal*, **1996**, 1, 213-7	5	6
48	Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. *Journal of Neurology*, **1995**, 242, 557-60	5.5	285
47	Partially saturated fluid attenuated inversion recovery (FLAIR) sequences in multiple sclerosis: comparison with fully relaxed FLAIR and conventional spin-echo. *Magnetic Resonance Imaging*, **1995** , 13, 513-21	3.3	17
46	Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. *Neurology*, **1995**, 45, 255-60	6.5	255

45	Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. *Neurology*, **1995**, 45, 1684-90	6.5	267
44	Medial temporal lobe atrophy in an open population of very old persons: cognitive, brain atrophy, and sociomedical correlates. *Neurology*, **1995**, 45, 747-52	6.5	41
43	Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. *Neurology*, **1995**, 45, 883-8	6.5	291
42	Multiple sclerosis therapy. A practical guide. *Drugs*, **1995**, 49, 200-12	12.1	16
41	Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. *Brain*, **1995**, 118 (Pt 6), 1601-12	11.2	157
40	Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. *Acta Neurologica Scandinavica*, **1994**, 90, 105-10	3.8	23
39	Visual rating of hippocampal atrophy: correlation with volumetry. *Journal of Neurology, Neurosurgery and Psychiatry*, **1994**, 57, 1015	5.5	24
38	Phase-Contrast Cine Mr Imaging of Normal Aqueductal CSF Flow: Effect of Aging and Relation to CSF Void on Modulus MR. *Acta Radiologica*, **1994**, 35, 123-130	2	63
37	Phase-contrast cine MR imaging of normal aqueductal CSF flow. *Acta Radiologica*, **1994**, 35, 123-130	2	51
36	Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. *Neuroradiology*, **1994**, 36, 382-7	3.2	47
35	Radiotherapy response of cerebral metastases quantified by serial MR imaging. *Journal of Neuro-Oncology*, **1994**, 21, 171-6	4.8	12
34	Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. *Journal of the Neurological Sciences*, **1994**, 122, 6-14	3.2	81
33	Evidence for atrophy of the corpus callosum in Alzheimer's disease. *European Neurology*, **1994**, 34, 83-6	2.1	28
32	T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone. *Acta Neurologica Scandinavica*, **1993**, 88, 80-6	3.8	14
31	A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. *Journal of the Neurological Sciences*, **1993**, 114, 7-12	3.2	744
30	Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. *Brain*, **1993**, 116 (Pt 5), 1077-94	11.2	224
29	Pre-and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer's disease. *Journal of the Neurological Sciences*, **1993**, 117, 175-8	3.2	15
28	Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone. *Journal of Neurology*, **1993**, 240, 305-8	5.5	21

27	Database for serial magnetic resonance imaging in multiple sclerosis. *Neuroradiology*, **1993**, 35, 362-6	3.2	5
26	SPECT, CT and MRI in a Turkish family with Huntington's disease. *Neuroradiology*, **1993**, 35, 525-8	3.2	4
25	Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. *American Journal of Roentgenology*, **1992**, 159, 1041-7	5.4	116
24	Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. *Journal of Neurology, Neurosurgery and Psychiatry*, **1992**, 55, 967-72	5.5	1021
23	White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. *Brain*, **1992**, 115 (Pt 3), 735-48	11.2	252
22	The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis. *Journal of Neuroimmunology*, **1992**, 40, 265-72	3.5	26
21	CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. *Acta Neurologica Scandinavica*, **1992**, 86, 291-7	3.8	44
20	Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. *Annals of Neurology*, **1992**, 32, 834-5	9.4	83
19	A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. *Neurology*, **1992**, 42, 63-7	6.5	89
18	Meningeal Gd-DTPA enhancement in multiple sclerosis. *American Journal of Neuroradiology*, **1992**, 13, 397-400	4.4	6
17	Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. *American Journal of Neuroradiology*, **1992**, 13, 1257-9	4.4	7
16	Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium- "enhanced" STIR imaging. *Neuroradiology*, **1991**, 33, 70-1	3.2	15
15	Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. *Journal of Neurology, Neurosurgery and Psychiatry*, **1991**, 54, 683-8	5.5	266
14	Magnetic Resonance Imaging Hyperintensities in Alzheimer's Disease-Reply. *Archives of Neurology*, **1991**, 48, 469-470		6
13	Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. *Neurology*, **1991**, 41, 1219-22	6.5	105
12	"Top of the basilar" syndrome: a comparison of clinical and MR findings. *Neuroradiology*, **1988**, 30, 293-8	3.2	12
11	Imaging of gray matter lesions in multiple sclerosis165-174		
10	Structural neuroimaging58-69		24

9	Use of Imaging in Multiple Sclerosis45-62	
8	DNA methylation classification in diffuse glioma shows little spatial heterogeneity after adjusting for tumor purity	1
7	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset	1
6	ExploreASL: an image processing pipeline for multi-center ASL perfusion MRI studies	1
5	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer's disease	2
4	Application of mechanistic methods to clinical trials in multiple sclerosis: the simvastatin case	1
3	Accelerated brain ageing and disability in multiple sclerosis	9
2	Data-driven detection of latent atrophy factors related to phenotypical variants of posterior cortical atrophy	1
1	Progression of regional grey matter atrophy in multiple sclerosis	1